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Parkin was originally discovered as a gene whose mutations are causative of 
familial parkinsonism. However, numerous subsequent evidences suggest that parkin 
also plays a role in the progression and development of a variety of cancer. 
In this thesis, I investigated the potential role of parkin in gliomagenesis and 
showed that parkin expression is dramatically reduced in glioma cells. I further 
showed that restoration of parkin expression in these cells promotes their arrest at G1 
phase and significantly mitigates their proliferation rate both in vitro and in vivo. 
Notably, the level of cyclin D1, but not cyclin E, is reduced in parkin-expressing 
glioma cells. Moreover, parkin expression also leads to a selective downregulation of 
Akt serine-473 phosphorylation and VEGF receptor 2 levels. Supporting this, cells 
derived from parkin null mouse exhibit increased levels of cyclin D1, VEGF receptor 
2 and Akt phosphorylation and divide significantly faster compared to their wild type 
counterparts, all of which are suppressed following the re-introduction of parkin into 
these cells. However, parkin-mediated effects on these components is dependent on 
its catalytic competency as a catalytically null parkin mutant failed to influence the 
expression of cyclin D1, phospho-Akt and VEGF receptor.  Interestingly, parkin 
expression also leads to the downregulation of two oncogenic microRNAs namely 
miR-21 and miR-155.  Importantly, analysis of parkin pathway activation revealed its 





Taken together, my study provides a mechanism by which parkin exerts its 
tumor suppressor function and a signature pathway of parkin that is of potential 
prognostic value. 







Gliomas are cancer of the glial cells and are among the most difficult 
cancers to treat because of the limited selection of anticancer drugs that could 
permeate through the blood brain barrier to reach the tumors. Although gliomas 
are considered as a rare disease with an incidence rate of about 1-2% as compared 
to other types of cancer, there is a high rate of recurrence even after complete 
surgical removal of the tumor. In addition to this, the median rate of survival of 
malignant glioma is usually about 12 months (Maher et al., 2001). Thus, it is 
important to understand the disease better in order to treat it more effectively. 
Broadly, gliomas include astrocytomas, ependymomas, medulloblastomas, 
meningiomas, oligodendrogliomas and pituitary adenomas. Astrocytomas are glial 
tumors derived from the star-shaped glial cells that are normally involved in 
several vital processes including neurotransmitter uptake and release, 
vasomodulation, and modulation of synaptic transmission (Kanu et al., 2009). 
Ependymomas are derived from cuboidal ependymal cells which line the 
cerebrospinal fluid (CSF)-filled ventricles in the brain and the central canal of the 
spinal cord (Gilbert et al., 2010), whereas oligodendrogliomas are derived from 
myelin forming cells of the central nervous system (Wen et al., 2008). 
Medulloblastomas are usually located around the region from the cerebellum to 
brain stem and they represent about 20% pediatric and adult brain tumors. 
Meningiomas are tumors that develop in the meninges covering the central 
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nervous system and it accounts for about 25% of all primary brain tumors. Finally, 
pituitary adenomas are usually benign tumors of the pituitary gland and they 
represent about 10% of all primary brain tumors. 
 
1.2 Glioma Prevalence and Epidemiology 
The annual incidence of malignant gliomas is approximately 5 cases per 
100,000 people (Louis et al., 2007). Malignant gliomas refers to the metastatic 
gliomas which are the WHO classified grade III and IV gliomas.  The most 
malignant type of glioma, glioblastoma multiforme (GBM) accounts for about 
50% of malignant gliomas. Other forms of malignant gliomas include 
astrocytomas and oligodendrogliomas, which together account for about 34% of 
all gliomas. The remaining 5-10% consists of less common tumors such as 
anaplastic ependymomas and gangliogliomas (Louis et al., 2007) (Fig. 1.1). The 
word “anaplastic” refers to dedifferentiation which is a distinctive feature as the 





Figure 1.1 Distribution of the different 
types of gliomas (Graph from Central 
Brain Tumor Registry of the United 
States, CBTRUS) 
  
The recorded incidence of gliomas has increased slightly over the past two 
decades as a result of advances in diagnostic imaging techniques (Fisher et al., 
2007). The incidence of malignant gliomas is 40% more common in men as 
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compared to women and twice as common in Caucasians compared to African 
populations. The median age of onset in patients at the time of diagnosis is 64 
years of age in the case of GBM and 45 years of age in the case of anaplastic 
gliomas (Fisher et al., 2007). About 5% of patients with malignant gliomas exhibit 
a family history of gliomas and a portion of these familial cases are associated 
with rare genetic syndromes, such as Turcot’s syndrome, neurofibromatosis type 1 
and 2 and the Li-Fraumeni syndrome (Farrell et al., 2007). 
 
1.3 Glioma Clinical Presentation and Imaging 
Patients with malignant gliomas may present with a variety of symptoms 
including headaches, nausea, vomiting, confusion, seizures, memory loss, focal 
neurological deficits and personality changes. Classical headaches observed in 
glioma patients are indicative of increased intracranial pressure and are most 
severe in the morning and may potentially cause insomnia for these patients.  
The medical diagnosis of gliomas is usually confirmed by magnetic 
resonance imaging (MRI) or computed tomography. These glioma imaging 
studies conventionally show a heterogeneously enhanced mass with edema in the 
surrounding cavity. In the case of GBMs, there are necrotic regions in the central 
areas of the tumors and more extensive peritumoral edema compared to anaplastic 
astrocytomas (Fig. 1.2) (Cha, 2006). 
Figure 1.2 MRI scan of a 51-year old 
man with frontal glioblastoma 
multiforme which shows a centrally 
necrotic frontal lobe mass with 
edema. (A) Pre-operation MRI image. 
(B) Post-operation MRI image. (Image 
from Cha, 2006) 
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MRI techniques like diffusion-weighted imaging (DWI) for tumor grade 
assessment, dynamic contrast-enhanced MRI to measure blood vessel 
permeability, perfusion-weighted imaging to measure relative cerebral blood 
volume are used more frequently as diagnostic aids and for monitoring of 
response to therapies (Young, 2007). DWI-MRI uses the principle that water 
diffusivity within the extracellular compartment is inversely related to the 
cellularity within the extracellular space. The basic principle of DWI-MRI 
measurement is as follows: the higher the level of cellularity, the lower the water 
diffusivity through the intracellular spaces between cells and hence a lower 
apparent diffusion coefficient (ADC). Based on this, DWI-MRI is commonly used 
to assess tumor grade (Fig. 1.3) and cellularity, post-operative injury, peritumoral 
edema and integrity of the white matter tract. 
 
 
Figure 1.3 DWI scans of different WHO grades astrocytomas. (Left) WHO grade II, 
Middle) WHO grade III, (Right) WHO grade IV astrocytomas (Image from Cha, 2006). 
  
There is also the use of proton magnetic resonance spectroscopy (1H-
MRS) to assist in the detection of the levels of metabolites and that could help to 
differentiate proliferating tumors from benign and necrotic lesions. For this 
imaging technique, samples from malignant glioma would show an increase in the 
choline peak and a decrease in the N-acetyl aspartate peak as compared to 
unaffected areas of the brain (Fig. 1.4A). These metabolites level changes have 
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moderate to high sensitivity (64%-95%) and high specificity (82%-100%) for 
identifying actively dividing tumors. In addition, the corresponding increase in 
lactate, an end-product of nonoxidative glycolysis in regions of tumors may 
correlate with hypoxia within the tumor tissues. However, this technique is not 
able to distinguish between malignant and benign tumors (Fig. 1.4B) (Allen, 
1972). 
 
Figure 1.4 1H-MRS imaging of 59 year-old woman with superior frontal anaplastic 
astrocytomas. (A) The centre of tumor mass reveals a marked increase in lactate (Lac), 
choline (Cho) and a decrease in N-acetyl aspartate (NAA) metabolite. (B) Corresponding 
lactate metabolite peaks detected within the tumor regions. (Image from Cha, 2006). 
 
 
1.4 Glioma Classification and Grading 
 Gliomas are classified and sub-categorized on the basis of 
histopathological manifestations and clinical presentations. They are graded on a 
World Health Organization (WHO) consensus-derived scale of I to IV according 
to the degree of malignancy as determined by various histological features and 
genetic alterations (Louis et al., 2007).   
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 According to WHO classification, Grade I gliomas are considered as 
biologically benign and can be completely eradicated by surgical resection. Grade 
II gliomas are low-grade malignant tumors that could potentially infiltrate 
surrounding brain tissues rendering them incurable by surgery. The mean survival 
rate for this group of patients is around 5 to 10 years. Grade III gliomas 
demonstrate much enhanced proliferation, anaplasia and angiogenic responses 
over grade II glioma with a mean survival rate of about 2 to 3 years. Finally, grade 
IV glioma which is the most prevalent and biologically aggressive is defined by 
hallmarks of unrestrained cellular proliferation, diffuse infiltration, increased 
angiogenesis, propensity for necrosis, resistance to apoptosis and rampant 
genomic instability. Grade IV gliomas are usually quite recalcitrant to 
radiotherapy and chemotherapy. Patients with Grade IV gliomas have a mean 
survival rate of around 9 to 14 months (Furnari et al., 2008). GBM (WHO grade 
IV) is one of the most common and malignant type of brain tumor that accounts 
for 50% of all incident cases of astrocytic and oligodendroglial tumors. Despite 
advances in surgery, chemotherapy and radiation therapy, the median survival rate 
remains dismal (about 12 months) (Bansal et al., 2006). 
 
1.5 Glioma Databases 
Towards better understanding and treatment of gliomas, a number of 
databases that capture and integrate data associated with glioma studies have been 
developed in recent years. Two of such glioma databases, Rembrandt and TGCA, 
are briefly described below. 
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1.5.1 REMBRANDT 
REpository for Molecular BRAin Neoplasia DaTa (REMBRANDT) is 
clinical glioma patients’ genomics database that leverages data warehousing 
technology to host and integrate clinical and functional genomics data from 
clinical trials involving patients suffering from gliomas. The knowledge 
framework can be used to provide researchers with the ability to perform ad hoc 
querying and reporting across multiple data domains, such as gene expression, 
chromosomal aberrations and clinical data. To date, Rembrandt contains data 
generated through the glioma diagnostic initiative from 1018 glioma specimens 




Fig. 1.5 REMBRANDT 





Through the use of Rembrandt, one is able to trace the expression level of 
a gene of interest in the various grades of glioma patients and its correlation with 
survival rate. And at the same time, the database also provides a platform for 
validation of gene signature derived from cellular or animal model studies. 
 
1.5.2 TCGA (The Cancer Genome Atlas) 
 The Cancer Genome Atlas (TCGA) is another comprehensive and 
coordinated effort by cancer researchers to accelerate the understanding of the 
Introduction     8 
 
molecular basis of cancer through the application of genome analysis technologies 
and large-scale genome sequencing. As a public resource, all TCGA data are 
deposited at the Data Coordinting Center for public access 
(http://cancergenome.nih.gov/). The first cancer that was studied by TCGA is 
glioblastoma and this database provides a network view of the pathways altered in 
the development of glioblastoma. Importantly, TCGA is able to integrate analysis 
of DNA copy number, gene expression and DNA aberration data to come out with 
a more defined core signaling pathways in glioblastoma in which we can compare 
against in our own studies. The only caveat is that TCGA at this moment 
comprises mainly GBM specimens and has thus less molecular heterogeneity than 
Rembrandt, which contains information on gliomas at different stages. 
 
1.6 Intervention and Treatment of Glioma 
 The care for glioma patients revolves around the management of common 
set of problems faced by brain tumor patients which include seizures, venous 
thromboembolism, cognitive dysfunction, fatigue and peritumoral edema (Wen et 
al., 2006). The standard therapy for the treatment of malignant gliomas involves 
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Table 1. Overview of current treatments for malignant gliomas (From Wen et al., 
2008) temozolomide (TMZ), procarbazine (PCV), lomustine (CCNU). 
 
1.6.1 Radiotherapy 
Radiotherapy is the mainstream treatment of malignant gliomas and is 
usually used in combination with surgery to increase the survival among glioma 
patients from about 3 to 4 months to 7 to 12 months (Stupp et al., 2005). A typical 
radiotherapy regime consists of 60 Gy of partial-field external-beam irradiation 
delivered 5 days per week in portions of 1.8 to 2.0 Gy, which represents the 
standard treatment for glioma patients after resection. Age appears to be an 
important factor in determining the effectiveness of radiotherapy. Radiotherapy 
performed on glioma patients who are 70 years of age or older produces only a 
modest benefit in median survival of about 29.1 weeks as compared to supportive 
care with a median survival of 16.9 weeks and elderly glioma patients generally 
have a worse prognosis than their younger counterparts (Keime-Guibert et al., 
2007). 
 
1.6.2 Surgical Resection 
 Surgical resection is the most common initial therapeutic approach for 
obtaining tissues for diagnosis and for “tumor debulking” (i.e. surgical removal of 
as much tumor tissues as possible) provided that neurological function is not 
compromised. Although glioma patients undergo maximal surgical resection 
whenever possible, malignant gliomas are usually infiltrative by nature and cannot 
be completely eliminated surgically. The benefits of surgical debulking include 
reduction of intracranial pressure that could result from the mass effect of the 
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tumor and provides tumor tissues for molecular studies and histological diagnosis. 
Advances in surgical technologies such as MRI-guided neuro-navigation, 
intraoperative mapping (Asthagiri et al., 2007) and fluorescence-guided surgery 
(Stummer et al., 2006) have increased the efficacy of surgical resection and 
improved the safety of surgery. 
 
1.6.3 Chemotherapy 
 Chemotherapy is gaining importance in the treatment of gliomas and is 
frequently used in combination with radiotherapy. One of the more commonly 
used chemotherapeutic drugs against gliomas is temozolomide. Temozolomide is 
a DNA alkylating agent that is approved for use in adult patients with anaplastic 
astrocytoma that failed to respond to other drug treatments. It is also approved for 
use during and after radiation therapy for patients newly diagnosed with GBM. 
The current first-line treatment for patients with glioblastoma is combined 
radiotherapy and temozolomide, followed by monthly doses of temozolomide 
after radiation treatment ends. The treatment of malignant gliomas using a 
combination radiotherapy plus temozolomide as compared with radiotherapy 
alone significantly increased the median survival from 12.1 months to about 14.6 
months (Stupp et al., 2005). Further to this, the survival rate at 2 years among the 
glioma patients who received radiotherapy and temozolomide is 16.1% greater 
than the survival rate among patients who received radiotherapy alone (Stupp et 
al., 2005).  
Another chemotherapeutic drug, carmustine is commonly being used to 
treat many types of brain tumors, including GBM, medulloblastoma, and 
anaplastic astrocytoma. Carmustine or bis-chloronitrosourea is a mustard gas-
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related α-chloro-nitrosourea compound used as a DNA alkylating agent in 
chemotherapy. It is usually administered into the vein via IV but can also be 
delivered through a wafer implant (Gliadel), which is surgically placed into the 
brain cavity after tumor removal. An interesting chemotherapeutic approach 
involves the implantation of biodegradable polymers containing carmustine 
(Gliadel Wafers, MGI Pharma) into the tumor bed to gradually kill off the residual 
tumor cells after the resection of the tumor. The use of these carmustine-
containing polymers in patients with malignant gliomas in a randomized, placebo-
controlled trial was shown to significantly increase their median survival from 
11.6 months to 13.9 months (Westphal et al., 2003). 
 Currently, anaplastic astrocytomas are treated with radiotherapy and either 
concurrent with adjuvant temozolomide or with temozolomide alone in the case of 
GBMs. However, despite optimal treatment, almost all malignant gliomas recur 
with a median time of progression time of 6.9 months after treatment with 
radiotherapy and temozolomide (Stupp et al., 2005). Despite intensive efforts in 
research for novel therapies, there remains a need for improvements in the 
treatment strategies of malignant gliomas. 
 
1.6.4 Targeted Molecular Therapy 
 The increasing understanding of the molecular pathogenesis of malignant 
glioma has produced a more directed use of targeted molecular therapies. The 
main focus has been on inhibitors that target receptor tyrosine kinases like EGFR 
(Rich et al., 2004), VEGFR (Batchelor et al., 2007) and PDGFR (Wen et al., 
2006) as well as inhibitors targeting intracellular signaling components such as the 
PI3K/Akt signaling pathway. Interestingly, these inhibitors when used as a single 
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agent often only exhibit modest activity with patient response rate of about 0 to 
15% (Chi et al., 2007). This response to single tyrosine kinase inhibitor could be 
attributed to coactivation of multiple tyrosine kinases together with redundant 
signaling pathways thereby limiting the activity of single inhibitors (Stommel et 
al., 2007). 
 As mentioned earlier, malignant gliomas are among the most vascularized 
human tumors and thus making them ideal targets for angiogenesis inhibitors (Jain 
et al., 2007). Irinotecan, one of the more common topoisomerase I inhibitor used 
is activated by its hydrolysis to SN-38 and this leads to the inhibition of both 
DNA replication and transcription. Bevacizumab, on the other hand, is a 
humanized monoclonal antibody that binds to vascular endothelial growth factor 
A to block angiogenesis, commonly used in a variety of cancers. A positive effect 
was observed in one of the angiogenesis inhibitor studies when the treatment of 
malignant gliomas using a combination of bevacizumab and irinotecan had 
lowered the incidence of haemorrhage. This combined regimen also increased the 
6 month rate of progression free survival from 21% to 46% as compared to 
patients who were already receiving temozolomide treatment. 
 With the increasing understanding of the molecular pathogenesis of 
gliomas, it may be possible in the future to select the most appropriate therapies 
on the basis of the patient’s tumor genotype. In the sections below, I shall provide 
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1.7 Glioma Pathogenesis and Signaling Pathways 
 Three major signaling pathways have been identified to contribute 
significantly towards the onset of gliomagenesis (Funari et al., 2008): 1) cell cycle 
signaling pathways, 2) growth factor-regulated signaling pathways and 3) 
mitogenic signaling pathways. Cell cycle signaling pathways relevant to 
gliomagenesis consist of the retinoblastoma and p53 signaling pathways which are 
involved in the regulation of cell cycle progression in tumor cells. In the growth 
factor-regulated signaling pathways, extracellular growth factors are involved in 
the cellular signaling of cell proliferation and signaling pathways implicated in 
promoting glioma development include those mediated by epidermal growth 
factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factor 
(FGF) and vascular endothelial growth factor (VEGF). And for mitogenic 
signaling pathways involved in gliomagenesis, the mitogen-activated protein 
kinase signaling pathway and the PI3K/PTEN/Akt signaling pathway are two 
major downstream effectors that shall be discussed herein. 
 
1.7.1 Cell Cycle Signaling pathways 
  The mammalian cell cycle is a highly conserved mechanism which is 
conventionally divided into 4 phases: G1 (first gap phase), S (DNA synthesis 
phase), G2 (second gap phase) and M (mitosis phase) (Murray et al., 1993). The 
progression through the cell cycle is regulated by sequential expression, activation 
and inhibition of cyclins, cyclin-dependent kinases (CDKs) and cyclin-dependent 
kinase inhibitors (CDKIs). In proliferating cells, there are certain checkpoints 
which functions as molecular switches that ensure certain critical events in the 
respective phases are completed before entry into the next phase. If the cells were 
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arrested at any of these checkpoints, they will either return back to G0, resting 
phase, re-differentiate or die by apoptosis so as to ensure that the non-repairable 










Figure 1.6 Stages of the cell cycle with the various regulators. Progression through cell 
cycles is tightly regulated by cyclin/CDK complexes and their inhibitors. 
  
The activation of the cell cycle proceeds after mitogenic stimulation. This 
requires the synthesis of cyclin D, which binds to and activates CDK4 and CDK6 
to allow the progression of the G1 phase of the cell cycle. The retinoblastoma 
protein (Rb) (which normally binds and inactivates E2F) is then phosphorylated 
by the active cyclin D-CDK4 or cyclin D-CDK6 complexes on serine residues at 
positions 788 together with 795. Upon its phosphorylation, Rb is released from the 
E2F transcription factor which results in trans-activation and de-repression of E2F 
transcription factor-target genes required for S-phase entry (Liu et al., 2001). This 
allows for the transcription of cyclin E by the E2F family members. Cyclin E then 
interacts with and binds to CDK2 towards the end of the G1 phase to form an 
active complex which further phosphorylates the Rb protein on threonine residues 
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at position 821 and 826 resulting in the full activation of E2F due to further 
dissociation of free E2F. The cyclin E-CDK2 complex is necessary for transition 
from the G1 phase into the S-phase through phosphorylation of NPAT (nuclear 
protein mapped to the AT locus). NPAT is associated with histone gene clusters 
and activates histone gene transcription which increases the expression of histones 
necessary for the assembly of newly synthesized DNA into chromatin (Ma et al., 
2000). The cyclin E-CDK2 complex also promotes centromere duplication via 
phosphorylation of the centrosomal proteins NPM (nucleophosmin)/B23, which 
results in its dissociation from the centrosome to trigger centriole duplication. This 
event is important for chromosomal segregation (Lacey et al., 1999). The 
progression of the cell cycle through the S-phase is regulated by cyclin A-CDK2 
complex and subsequently, by cyclin A- CDK1 complex when the DNA 
replication is completed, which drives the cell through G2 phase. The cyclin A-
CDK1 complex phosphorylates the ORC (origin recognition complex) subunit 
Orc1 during mitosis to prevent its interaction with chromatin in order to prevent 
further DNA replication (Li et al., 2004). At the G2/M transition phase, cyclin A 
is degraded and CDK1 associates with the newly synthesized cyclin B for 
progression through mitosis. In the late stages of mitosis, the cyclin B-CDK1 
complex is disassembled due to the degradation of cyclin B by the anaphase-
promoting complex (APC), an E3-ubiquitin ligase (Harper et al., 2002). 
Abnormalities in the cell cycle machinery that alter the ability of the cell to 
arrest itself at the G1 or G2 phase of the cell cycle would result in unrestrained 
cellular proliferation and promote tumorigenesis. For example, loss of Rb activity 
promotes unregulated G1-S phase transition and increases cell cycle progression. 
Similarly, p53, a tumor suppressor, is also frequently mutated or deleted in human 
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tumors and is often found mutated or lost early in glioma formation (Nozaki et al, 
1999). Clearly, aberrant Rb- and p53-mediated signaling can contribute to 
gliomagenesis, as discussed below. 
 
1.7.2 Retinoblastoma (RB) Signaling pathway in gliomagenesis 
 Supporting a role for Rb in gliomagenesis, the Rb1 gene that is mapped to 
chromosome 13q14 is mutated in 25% of known high grade astrocytomas. Further 
to this, the allelic loss of 13q arm typifies the transition from a lower to 
intermediate grade gliomas (Henson et al., 1994). In addition, the cell cycle 
machinery proteins CDK4 and CDK6 (Fig. 1.6 and 1.7) that phosphorylate Rb are 
found to be frequently amplified and are responsible for the functional 
inactivation of Rb in 10% to 15% of high-grade gliomas (Reifenberger et al., 
1994, Costello et al., 1997). This CDK4/6-mediated Rb downregulation is further 
promoted by the inactivation of critical negative regulators of both CDK4 and 
CDK6, namely p16Ink4a and p14ARF (Serrano et al., 1993). Notably, both p16Ink4a 
and p14ARF can be inactivated by hypermethylation at CpG positions (Costello et 
al., 1996) or by allelic loss, which occur in 50% to 70% of high grade gliomas and 
about 90% of cultured glioma cell lines (Fueyo et al., 1996). 
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Figure 1.7 Altered signaling pathways in the development of malignant gliomas 
(From Wen et al., 2008) 
 
1.7.3 p53 Signaling pathway 
 Besides Rb, p53 represents another tumor suppressor that is often 
dysregulated in gliomas. The transcription factor p53 is widely regarded as a 
“guardian of the genome”, whose chief function is to prevent the proliferation of 
cells with unstable genomes primarily through the halting the cell cycle at the G1 
phase (Vousden et al., 2002). When needed, p53 can also activate apoptosis. Upon 
its post-translational modification by various cytotoxic and genotoxic stress-
sensing proteins, p53 becomes stabilized and binds transcriptionally to promoters 
of over 2500 effectors genes (Levine et al., 2006). One of the best characterized 
p53 effector genes is the CDNK1A which encodes for the CDK2 inhibitor, p21 
(Harper et al., 1993). The inhibition of CDK2 prevents its association with cyclin 
E which is necessary for G1 phase to S phase transition. The loss of p53 function 
either through point mutations or the loss of chromosome 17 where the gene 
resides is a frequent event in the cellular progression of secondary gliomas (Louis, 
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1994). The importance of the p53 pathway in gliomagenesis is further emphasized 
by the increased incidence of gliomas in Li-Fraumeni syndrome, a familial cancer-
predisposition syndrome associated with germline p53 mutations (Srivastava et 
al., 1990). 
 
1.7.4 Growth Factor-Regulated Signaling Pathway 
 Aside from promoting cell cycle dysregulation, gliomas may potentially 
activate growth factor receptor-driven pathways to augment its growth by a 
combination of mechanisms such as overexpression of both of the ligands and the 
receptors, amplification or mutation of the growth receptor leading to constitutive 
activation of the downstream signaling pathway in the absence of ligand. The 
EGF, PDGF, FGF and VEGF signaling pathways in particular play important 
roles in the development of the central nervous system (CNS) as well as in 
gliomagenesis. Notably, directed therapy against these potentially critical 
signaling pathways is currently in progression (Kanu et al, 2009). 
 
1.7.5 EGF Receptor Signaling Pathway  
 Epidermal growth factor receptor (EGFR) is a transmembrane protein 
belonging to the erbB/HER family of receptor tyrosine kinases (RTKs) which 
includes four members defined as ErbB-1/EGFR/HER1, ErbB-2/HER2/neu, 
ErbB-3/HER3 and ErbB-4/HER4 (Citri et al., 2006). The EGFR gene encodes a 
protein containing 1186 amino acids, 621 residues of which comprise the extra-
cellular region. After EGFR dimerization, multiple residues of the cytoplasmic 
kinase domain are autophosphorylated and several downstream adaptors protein 
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are recruited under the plasma membrane, including Grb2, Shc or Dok-R for 
activation of the different signal transduction pathways. 
EGFR gene amplification occurs in about 40% of all GBM and the 
amplified gene is frequently rearranged (Wong et al., 1992). One of the most 
common EGFR mutations is the mutation found between exons 2-7 previously 
known as EGFRvIII, EGFR, or EGFR* with an occurrence of about 20%-30% 
in all GBM and about 50%-60% out of those that have amplified wild-type EGFR 
(Frederick et al., 2000). EGFRvIII is an important glioma target as shown by the 
capacity of this mutant to enhance the tumorigenic behavior of human GBM cells 
by reducing apoptosis, increasing cellular proliferation (Narita et al., 2002). In a 
similar manner, EGFRvIII mutations was similarly shown to malignantly 
transform murine Ink4a/Arf-null neural stem cells (NSCs) or primary astrocytes 
obtained from mouse brains (Bachoo et al., 2002). 
 
1.7.6 PDGF Receptor Signaling Pathway 
 The PDGF family consists of five isoforms that are homodimers of A‐, B‐, 
C‐, and D polypeptide chains, i.e. PDGF‐AA, ‐BB, ‐CC, and ‐DD, and a 
heterodimer PDGF‐AB (Heldin et al., 2002). The A‐ and B‐chains are synthesized 
as inactive precursors, but are cleaved during secretion from the producer cell and 
are present extracellularly in active forms. The PDGF isoforms exert their cellular 
effects by binding to structurally similar α‐ and β-	 PDGF receptor (PDGFR) 
tyrosine kinases. Each PDGFR contains five extracellular Ig‐like domains and an 
intracellular tyrosine kinase domain to which PDGF bind and activate by 
ligand‐induced receptor dimerization. The PDGF α‐ and β‐receptor homo‐ and 
heterodimers induce similar but not identical cellular effects. Almost all dimeric 
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receptor complexes mediate potent mitogenic effects with the exception of αα 
heterodimers and ββ homodimers, which mediate chemotaxis of smooth muscle 
cells and fibroblasts (Eriksson et al., 1992). 
 PDGFs and PDGFRs are frequently overexpressed in glioma tumor cell 
lines and surgical resection samples, and their expression levels appear to 
correlate with tumor grade (Hermanson et al., 1992). The expression of PDGFRs 
especially PDGFRα and its activating ligand PDGF-A and PDGF-B are 
particularly enhanced in high-grade gliomas while high expression of PDGFRβ 
occurs in proliferating endothelial cells in GBM (Di Rocco et al., 1998). In 
comparison to EGFR, the amplification or rearrangement of PDGFR is less 
common but a rare oncogenic deletion mutation in exon 8 and 9 of PDGFRα has 
been described to be constitutively active and enhances tumorigenicity (Clarke et 
al., 2003). PDGF-C and PDGF-D which require proteolytic cleavage for activity 
are also found to contribute to gliomagenesis (Lokker et al., 2002). The elevated 
coexpression of the various PDGFs and PDGFRs could potentially activate the 
range of autocrine and paracrine loops for activation of the downstream survival 
signaling pathway. The secretion of PDGF-B was also shown to enhance glioma 
angiogenesis through the stimulation of endothelial cells expression PDGFRβ to 
express vascular endothelial growth factor (VEGF) (Guo et al., 2003). 
 In addition to glial cell precursor, PDGFα and PDGFR have been shown to 
be able to stimulate NSCs in the adult subventricular zone of mouse brains to 
generate glioma-like lesions (Jackson et al., 2006). Further, transgenic mice over-
expressing PDGF-B exhibit increased tendency to form oligodendrogliomas (Dai 
et al., 2001) and increased overall incidence of tumor formation (Shih et al., 
2004). 
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1.7.7 FGF Receptor Signaling Pathway 
 In addition to both EGFRs and PDGFRs, FGF receptor (FGFR) pathway is 
also implicated in the progression of gliomagenesis. The expression of both FGF 
and FGFR1 is significantly increased in GBM (Morrison et al., 1994). 
Interestingly, lower-grade astrocytomas expressed higher levels of FGFR2 and as 
these tumors progressed to higher grade gliomas, they switched expression from 
FGFR2 to FGFR1 (Yamaguchi et al., 1994).  
 
1.7.8 VEGF Receptor Signaling Pathway 
 Vascular endothelial growth factor (VEGFs) ligands and receptors 
(VEGFRs) regulate a wide variety of physiological events which include vascular 
development, lymphangiogenesis and angiogenesis. VEGF consists of a family of 
homodimeric glycoproteins which are essential for the embryonic development of 
the blood vascular system (vasculogenesis), lymphatic system 
(lymphangiogenesis) and formation of new blood vessels from pre-existing blood 
vessels (angiogenesis). In the mammalian system, there are a total of 5 members 
in the VEGF family namely VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta 
growth factor (PLGF). In humans, VEGF-A165 is the most abundant and 
catalytically active form and is expressed as a 46kDa homodimer composed of 
two 23 kDa subunits and is produced by a range of cells including vascular 
smooth muscle cells, tumor cells and macrophages (Berse et al., 1992). These 
VEGF ligands bind to three different but structurally similar VEGFR tyrosine 
kinases namely VEGFR-1, VEGFR-2 and VEGFR-3.  
VEGFR-1 (Flt-1) is expressed on monocytes, vascular endothelial cells, 
macrophages, haematopoietic stem cells and is important for development of 
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haematopoietic stem cells. VEGFR-2 (Flk-1/KDR) is essential for the 
development of vascular endothelial cells and is expressed mainly on lymphatic 
and vascular endothelial cells. VEGFR-3 on the other hand is needed for 
lymphatic endothelial cells development and is expressed mainly on lymphatic 
endothelial cells (Holmes et al., 2007). Although predominantly found on 
endothelial cells, VEGFR have also been detected on cancer cells including 
gliomas (Zhang et al., 2008), suggesting a possible autocrine effect on their 
growth. 
VEGF plays a key role in the vascularization process of a growing tumor. 
During the development of the tumor, cells within the expanding mass of the 
tumor are frequently deprived of oxygen because of their great distance from the 
nearest blood vessels. As a consequence, regions rich in hypoxia begin to form 
and it increases the transcription rate and the stability of the messenger RNAs of 
the VEGF (Shinkaruk et al., 2003). As a tumor increases in size, there is a demand 
for an increase in density in the network of blood vessels to provide sufficient 
oxygen and nutrients to the growing tumor, and hence the VEGF signaling 
pathway plays an important role in the growth of the tumor. Malignant glioma like 
GBMs are among the most highly vascularized of all solid tumors and 
microvascular hyperplasia is a common feature of transition from a low-grade 
glioma (anaplastic astrocytomas) to high-grade malignant glioma (GBMs) (Maher 
et al., 2006). The levels of VEGF mRNA and protein are highly expressed in 
glioma cells with malignant GBMs producing more VEGF than low grade 
anaplastic astrocytomas (Chaudhry et al., 2001). The inhibition of VEGFR kinase 
using the small molecule inhibitor of Raf, AAL881 leads to inhibition of glioma 
xenograft growth (Sathornsumetee et al., 2006). 
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1.7.9 Mitogenic Signaling Pathways 
 Under normal conditions, the stimulation of cellular proliferation requires 
the regulated activation of mitogenic signal transduction pathways through growth 
factor binding, contact with extracellular matrix (ECM) or cell-cell adhesion. In 
gliomas, many of the mitogen-specific membrane receptors are however present 
in a constitutively active form, which concomitantly leads to enhanced activation 
of downstream effector pathways. Genomic alterations in gliomas that amplify 
these signaling pathways thus greatly reduce their dependency on exogenous 
growth factor signaling, and as a result, encourage their uncontrolled cell division, 
survival and motility. Two important downstream pathways that are of particular 
relevance to gliomagenesis are the mitogen-activated protein kinase (MAPK) 
signaling pathway and the PI3K/PTEN/Akt signaling pathway, which are 
discussed in more detail below. 
 
1.7.10 MAPK Signaling Pathway 
 Cell surface signals for the mitogen-activated protein kinase (MAPK) 
pathway can be transduced by both the receptor tyrosine kinases (RTKs) and 
integrins. Integrins are membrane-bound ECM receptors that facilitate the 
interaction between the ECM and the cytoskeleton. Integrins bind to cytoplasmic 
anchor proteins to synchronize the association of integrins with actin filaments to 
create a focal adhesion complex upon contact adhesion to ECM. Following this, 
numerous molecules of focal adhesion kinase (FAK) cluster at these complexes 
and become activated by cross phosphorylation, which in turn, activates a 
signaling cascade that leads to the phosphorylation of extracellular signal-
regulated kinase (ERK) through the activation of Ras. This activation of Ras is 
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facilitated by the recruitment of the adaptor protein Grb2 and the Ras guanine 
nucleotide exchange factor SOS to phosphorylate FAK at the plasma membrane 
or through Src-dependent phosphorylation of p130Cas (Fig. 1.8) (Schlaepfer et al., 
1997). 
 
Figure 1.8 MAPK signaling pathway in growth and differentiation. (Adapted from 
www.cellsignal.com). 
   
Similarly, RTKs are able to activate the MAPK pathway through growth 
factor signaling. The binding of growth factors to their cognate receptors results in 
receptor dimerization and trans-phosphorylation that create binding sites for 
adaptor protein complexes such as Grb2/SOS. The recruitment of Grb2/Sos to the 
activated receptor is important for the activation of Ras. Once the Ras-GTPase is 
activated, it phosphorylates Raf kinase (or MAPKKK) which in turn 
phosphorylates MEK. MEK is a dual specific kinase that is responsible for the 
phosphorylation of ERK. The activated ERK then enters the nucleus and 
phosphorylates a number of transcription factors that regulate the expression of 
genes promoting cell cycle progression, like for example cyclin D1. 
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1.7.11 PI3K/PTEN/Akt Signaling Pathway 
 The class 1A family of phosphoinositide 3-kinases (PI3K) are 
heterodimers recruited to activated RTKs and adaptor proteins through their 
regulatory subunit in which there is a total of 5 isoforms namely p85α, p55α, p50α 
(PIK3R1), p85β (PIK3R2); and p55γ (PIK3R3). These isoforms are encoded by 3 
genes shown within parenthesis (i.e. PIK3R1-3). The PI3K are currently grouped 
according to the catalytic isoform present namely: p110α, p110β and p110γ which 
are encoded by PIK3CA, PIK3CB and PIK3CD genes respectively (Hawkins et 
al., 2006). PIK3CA gain-of-function point mutants have been identified in a 
variety of tumors including GBMs and the frequency of mutation is as high as 
15% (Gallia et al., 2006). Further, elevated expression of PIK3CD gene has also 
been found in GBMs (Kang et al., 2006).  
Upon activation, PI3K phosphorylates its lipid substrate 
phosphatidylinositol 4,5-biphosphate [PtdIns(4,5)P2] to form phosphatidylinositol 
3,4,5-triphosphate [PtdIns(3,4,5)P3], an intracellular lipid second messenger 
(Hawkins et al., 2006). This process is opposed by the tumor suppressor, PTEN 
(phosphatase and tensin homolog) located on chromosome 10 which functions as 
a lipid phosphatase that dephosphorylates PtdIns(3,4,5)P3 (Di Cristofano et al., 
2000). Notably, PTEN is frequently mutated or deleted in human cancers 
including gliomas (Vivanco et al., 2002). The tumor suppressor is inactivated in 
50% of malignant gliomas by mutations or epigenetic mechanisms resulting in 
unrestrained PI3K signaling in these tumors (Knobbe et al., 2003). The genomic 
loss of PTEN would result in the accumulation of high levels of PtdIns(3,4,5)P3 
and would potentially lead to the constitutive activation of the PI3K pathway. 
Interestingly, PTEN inactivation was also found to be associated with an increase 
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in angiogenesis which coincides with the progression of malignant tumors (Xiao 
et al., 2005). In quiescent and differentiated cells with high levels of PTEN, the 
phosphatase was shown to fulfill essential roles in the maintenance of genomic 
integrity mainly through centromere stabilization and DNA repair (Shen et al., 
2007). Genetic studies in familial cancer predisposition syndromes have shown 
that a number of PTEN point mutants have mutations located within the PTEN 
localization domain. This resulted in the aberrant sequestration of PTEN into 
either the cytoplasm or nucleus, and the resultant mislocalization of PTEN 
contributes to the loss of its tumor suppressor function (Denning et al., 2007). 
 Among the numerous signaling proteins recruited to the membrane and 
activated by PtdIns(3,4,5)P3 is protein kinase B (PKB) or Akt. PtdIns (3,4,5)P3 
recruits and anchors Akt to the plasma membrane via association with its 
pleckstrin homology (PH) domain. The kinase then undergoes a conformation 
change that allows its phosphorylation and activation by PDK1 and PDK2. The 
complete activation of Akt requires phosphorylation of its 2 regulatory residues, 
i.e. threonine 308 (Thr 308) on the kinase domain and serine 473 (Ser 473) on the 
hydrophobic domain, by PDK1 and PDK2 respectively (Sarbassov et al., 2005). 
The phosphorylation of Akt on Ser 473 by PDK2 (thought to be composed of 
mTOR/Rictor/GβL and mSin1 complex) augments the Akt activity by about 10-
fold. It is noteworthy that 85% of the diffuse glioma patient samples have 
increased Akt activity as compared to controls (Wang et al., 2004). Further, an 
Akt phosphatase, PHLPP (PH domain leucine-rich repeat protein phosphatase) 
which dephosphorylates Akt at Ser 473 position is under-expressed in GBM cells 
lines. These modifications would result in a constitutively activated Akt 
environment that would enhance cellular proliferation. 
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Taken together, it is apparent a cancer cell (like a glioma cell) can exploit 
multiple strategies that subvert normal cell cycle regulation to promote its growth. 
Besides the components and pathways mentioned above, it is perhaps noteworthy 
to highlight that the ubiquitination pathway, normally associated with protein 
degradation and quality control, also has important roles to play in cancer.  
 
1.7.12  MicroRNAs 
 MicroRNAs (miRNAs) are a recently discovered class of evolutionarily 
conserved single-stranded non-coding RNA molecules of about 18-25 nucleotides 
that regulate gene expression at the post-transcriptional level through binding to 
target mRNA. The miRNA are derive from the processing of long RNA 
transcripts encoded by miR genes and are involved in numerous cellular processes 
including proliferation, differentiation, apoptosis and metabolism (Bartel, 2004). 
The miRNAs have been predicted to target and control the expression of at least 
30% of the mammalian genome (Filipowicz et al., 2008) and deregulation of 
miRNAs can potentially be involved in different human pathological diseases 
including cancer. 
 The generation of miRNA is multi-step process which includes numerous 
post-transcriptional modifications. In the initial step, the RNA polymerase II 
transcribes the miR genes to generate the pri-miRNA transcripts. A nuclear 
microprocessor which contains the RNase III enzyme, Drosha and a double 
stranded RNA-binding protein, DGCR8 (Digeorge syndrome critical region gene 
8) converts the pri-miRNA into ~70 nucleotide miRNA precursor, pre-miRNA. 
The pre-miRNA stem-loop structures are then transported to the cytoplasm 
through the exportin 5 complex (Denli et al., 2004). Dicer, a cytoplasmic 
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endonuclease together with its co-factors TRBP (TAR RNA binding protein) and 
PACT (PKR-activating protein) would cleave the pre-miRNA stem loop forming 
a 21-24 bp duplex miRNA. The miRNA is then loaded onto the RNA induced 
silencing complex (RISC) containing argonaute (AGO) proteins and degradation 
of the target mRNA would occur only when the miRNA and the target mRNA is a 
complementary match to each other (Diederichs et al., 2007). 
 An estimation of more than 1000 miRNA has been identified and are 
involved in a wide variety of diseases including cancer. miR-15a and miR-16 are 
found frequently deleted  in chronic lymphocytic leukemia (CLL) (Calin et al., 
2002) interestingly more than 50% of the current known miR genes were found to 
be located among common fragile sites or chromosomal regions showing 
amplification, translocation or deletions in cancer (Calin et., 2004). Several other 
tumor types which include colon, breast and lung cancer have been associated 
with deregulation of miRNA expression (Lu et al., 2005). 
 
1.7.12.1 MicroRNA-21 (miR-21) 
 miR-21 was initially discovered to be highly elevated in all high grade 
glioma samples from patient tissues and early passage from GBM cultures (Chan 
et al., 2005). In a large-scale study of miRNA expression in 540 human samples 
derived from 6 solid tumor types, miR-21 was the only miRNA upregulated in all 
tumor types analysed which includes the breast, lung stomach, colon, pancreas 
and prostate (Volinia et al., 2006). A number of other independent studies have 
also shown elevated levels of miR-21 in ovarian cancer (Nam et al., 2008), 
cervical carcinoma (Lui et al., 2007), papillary thyroid carcinoma (Tetzlaff et al 
2007), hepatocellular carcinoma (Kutay et al., 2006) and numerous head and neck 
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cancer cell lines (Tran et al., 2007). Further to this, miR-21 was also found to be 
upregulated in leukemic cancers and its expression is dramatically higher by about 
10-folds in patients with chronic lymphocytic leukemia (CLL) as compared to 
normal lymphocytes (Fulci et al., 2007). 
 miR-21 was found to be overexpressed in even low grade gliomas such as 
astrocytomas (WHO Grade II) (Conti et al., 2009) that is characterized by slower 
proliferation rate as compared to GBM. Interestingly, miR-21 was described to 
regulate the expression of two tumor suppressor genes, PTEN (phosphatase and 
tensin homolog) (Meng et al., 2007) and TPM1 (Tropomyosin 1) (Zhu et al., 
2008). miR-21 has been shown to target various signaling pathways of p53, TGF-
β and mitochondrial apoptosis pathways (Papagiannakopoulos et al., 2008). The 
direct targets of miR-21 that have been identified are p63, p53 activators JMY 
(Junction-mediating and regulatory protein), TOPORS (an E3 ubiquitin protein 
ligase), TP53BP2 (Tumor protein p53 binding protein 2), HNRNPK 
(Heterogeneous nuclear ribonucleoprotein K) and DAXX (Death domain 
associated protein) which serve as p53 stabilizers by interfering with MDM2 or 
serve as co-factors in assisting p53 in the activation of genes that induces growth 
arrest and apoptosis. These array of proteins are essential for the proper 
functioning of p53 and by targeting these genes, miR-21 can impair p53 response 
to stimuli such as DNA damage. 
 miR-21 also regulates the TGF-β pathway by direct targeting of the 
TGFBR2 and TGFBR3 receptors and DAXX can mediate TGF-β apoptosis 
(Papagiannakopoulos et al., 2008). miR-21 also helps to maintain the invasiveness 
of glioma cells by targeting inhibitors of MMPs (matrix metalloproteinases). 
MMPs are a group of zinc-dependent endopeptidases involved in the degradation 
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of the extracellular matrix and their levels are usually significantly upregulated in 
correlation with invasiveness in gliomas (Nakada et al., 2003). miR-21 supposedly 
regulates the activity of MMPs through their inhibitors RECK and TIMP3 
(Gabriely et al., 2008). 
 PDCD4 (programmed cell death 4) was previously described as a target of 
miR-21 in glioblastoma cell line (Chen et al., 2008) and in colorectal cancer 
(Asangani et al., 2008). PDCD4 could potentially inhibit translation through its 
interaction with a factor that initiates translation of eIF4A and eIF4G and also 
inhibits cellular proliferation through activation of p21 (Gӧke et al 2004). 
 
1.7.12.2 MicroRNA-155 (miR-155) 
 miR-155 is processed from an exon of a non-coding RNA transcribed from 
the B-cell Integration Cluster (BIC) located on chromosome 21 and has been 
found to be involved in a variety of cellular processes including inflammation, 
immunity and haematopoiesis. The deregulation of miR-155 has been shown to be 
implicated in different kinds of diseases like cancer, viral infections and 
cardiovascular diseases. miR-155 has been designated as a component of the 
primary macrophage response to different types of inflammatory mediators such 
as the induction of miR-155 by a bacterial lipopolysaccharide (LPS) in a human 
monocytic cell line (O’Connell et al., 2007). 
 miR-155 was found to be responsible for the suppression of apoptosis in 
human T-cell leukemia, Jurkat cell line and in MDA-MB-453 breast cancer cell 
line through mitigation of caspase-3 activity (Ovcharenko et al., 2007). The 
overexpression of miR-155 was shown to decrease the levels of TP53INP1 (tumor 
protein 53-induced nuclear protein 1 which is a nuclear protein that is able to 
Introduction     31 
 
induce cell cycle arrest and apoptosis through caspase-3 activation (Gironella et 
al., 2007). There was observed high expression level of miR-155 in Reed-
Sternberg cells of Hogkin’s Lymphoma and also in the lymphocytic and 
histiocytic cells of the variant nodular lymphocyte-predominant Hogkin’s 
Lymphoma (Kluiver et al., 2005). 
 In addition, miR-155 was found to be overexpressed in several solid 
tumors such as breast cancer (Volinia et al., 2006), thyroid carcinoma (Nikiforova 
et al., 2008), lung carcinoma (Volinia et al., 2006), pancreatic ductal 
adenocarcinoma (Lee et al., 2007) and colon cancer (Volinia et al., 2006). 
 
1.8 Ubiquitin and E3 ligases in Cancer 
 The timely synthesis and degradation of the multitude of cell cycle 
regulatory proteins via ubiquitin modification by various ubiquitin ligases (E3) is 
another layer of control that the cell has over its division cycle. Accordingly, 
dysfunction in the ubiquitin-proteasome pathway that disrupts the delicate 
maintenance of protein homeostasis in the cell could result in the accumulation of 
unwanted oncogenic proteins or accelerated degradation of tumor suppressors 
leading to the potential onset of oncogenesis. 
Ubiquitin is a small 76 amino acid modifier that tags target proteins in a 
highly specific manner through a highly conserved process known as 
ubiquitination. Similar to phosphorylation, the modification of proteins with 
ubiquitin is common in normal as well as in pathological cellular processes. 
Ubiquitination was initially described as the process that labels proteins for 
degradation through the ubiquitin-proteasome degradation pathway (Hershko et 
al., 1998). However with time, a number of distinct ubiquitin-mediated functions 
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have evolved such as regulation of protein trafficking, enzyme activity regulation 
and assembly of protein signaling complex that may or may not involve substrate 
degradation (Mukhopadhyay et al., 2007). The mechanism of ubiquitination 
involves the attachment of ubiquitin to the substrate through the sequential action 
of 3 consecutive enzymes (Fig. 1.9). The first step involves the activation of 
ubiquitin by the formation of thioester bond with the ubiquitin-activating enzyme, 
E1 and this is followed by the E1 delivering the activated ubiquitin to the E2 
ubiquitin-conjugating enzyme. The final step involves the transfer of ubiquitin 
from E2 to a lysine residue in the protein substrate catalyzed by E3 ligases which 
determine the substrate specificity. The ubiquitin molecule contains seven lysine 
residues at positions 6, 11, 27, 29, 33, 48 and 63, and polyubiquitination can occur 
at any of these lysine residues (Pickart, 2000). Monoubiquitination of proteins can 
also occur. Notably, both monoubiquitination and K63-linked polyubiquitination 
are not typically associated with proteasome-mediated degradation. Thus, the 
process of ubiquitin conjugation can result in ubiquitin chains of different length, 
topologies and functional outcomes (Ikeda et al., 2008). There are many proteins 
known to be regulated by the ubiquitination process and these proteins include 
those that control cellular processes such as cell cycle progression, gene 





















Fig. 1.9 Protein Ubiquitination. (Left) Ubiquitin-proteasome system. (Right) 
Ubiquitination topologies and their roles (adapted from Lim KL, 2007 and Tan et al., 
2009). 
E3 ubiquitin ligases are considered one of the most important aspects of 
the ubiquitin conjugation machinery as they are the ones that bind directly to their 
target that determine substrate specificity. The numerous ubiquitin ligases are 
classified according to different categories dependent upon their structural 
configuration and mechanism of action. They are often grouped according to the 
presence of either U-box, HECT or RING domain (Nakayama et al., 2006). In 
certain cases, the core of the ubiquitin ligase consist of several proteins like in 
SCF complex composed of several proteins like RBX, SKP1, CUL1 and a 
variable substrate specific F-box protein to form a multi-subunit ubiquitin ligase. 
There are several examples of E3 ligases that have been linked to the development 
of cancer. Depending on its substrate specificity; an E3 can either function as a 
tumor suppressor or promoter (Nakayama et al., 2006). Examples of E3 ligases 
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that function as tumor suppressors include the Elongin B/C-CUL2-VHL E3 ligase 
complex and BRCA1 (breast cancer suspceptibility gene 1). The Elongin B/C-
CUL2-VHL E3 ligase complex suppresses tumor vascularization through 
degradation of HIF (hypoxia-inducible factor) via interaction with VHL (von 
Hippel-Lindau) protein in the complex (Kaelin, 2007). This degradation of HIF 
prevents the activation of hypoxia-inducible genes such as VEGF which is 
responsible for tumor vascularization. BRCA1 on the other hand is responsible for 
the formation of nuclear foci, essential for the repair of damaged DNA (Bennett et 
al., 2008). The expression of truncated or inactive BRCA1 protein is strongly 
linked to the development of ovarian and breast cancer (Hashizume et al., 2001). 
On the other hand, examples of E3 ligases which have oncogenic capacity include 
Hdm2 (human double minute 2) and HECT-type E3 ligase Nedd4-1. Under 
normal cellular conditions, the activation of Hdm2 allows it to bind and target p53 
for degradation, which represses the p53 signaling pathway leading to faster cell 
cycle progression (Vousden et al., 2005). Nedd4-1, a similar oncogenic E3 ligase 
was reported to mediate both monoubiquitination and polyubiquitination-
dependent proteasomal removal of PTEN (a tumor suppressor involved in the 
suppression of PI3K/Akt signaling pathway) in vitro (Fouladkou et al., 2008). 
Surprisingly, an E3 ligase known as parkin that was originally associated with 
Parkinson’s disease (PD) has recently emerged as a new player in cancer. That 
two disparate diseases such as PD and cancer may share common mechanism is as 
intriguing as it is fascinating. In the section below, I shall briefly discuss the 
salient features of PD and its potential relationship with cancer. 
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1.9 Parkinson’s Disease (PD) and Cancer 
PD is a major neurodegenerative disorder characterized principally by a 
rather selective loss of melanin-positive, dopaminergic neurons in the substantia 
nigra pars compacta (SNpc) of the midbrain and the frequent presence of 
intraneuronal protein aggregates known as Lewy bodies (LBs) that are composed 
predominantly of fibrillar α-synuclein. On the other hand, cancer is a group of 
diseases that is characterized by two main features: i) uncontrolled growth of the 
cells in the human body and ii) the ability of these cells to migrate from the 
original site and spread to distant sites (metastasis), which can result in death if 
not controlled. Notably, both PD and cancer are thought to arise from gene-
environment interaction with age as the singular most important risk factor 
(Migliore et al., 2002). Even though the exact mechanisms of aging remains 
incompletely defined, the aging process is likely to bring about cellular changes 
that would play an important role in linking the two disorders.  
As disparate as PD and cancer might appear to be at first glance, emerging 
evidence suggests interesting relationship between the two disorders. For 
example, Doshay noted as early as nearly six decades ago that “for reasons as yet 
unclear, cancer is phenomenally rare in paralyses agitans (old name for PD)” (25). 
We now know from numerous reported epidemiological studies that most cancer 
rates are lower in patients with PD compared with those in the general population 
and that the risk of dying from cancer is lower in PD patients than in the general 
population, indicating that PD might provide some form of “biologic protection” 
against several types of cancers. For example, in a large population cohort study 
involving 10,322 parkinsonian patients, there was an overall reduction in cancer 
mortality in both smoking and non-smoking related cancers (Vanacore et al., 
Introduction     36 
 
1999). This trend is essentially observed in another related study involving more 
than 14 000 patients with a primary diagnosis of PD.  
 
Figure 1.10 The Relative Risk of Cancer from various sites in both men 
and women with Parkinson’s Disease. (Figure from Olsen et al., 2005) 
 
However, it is important to recognize that a few types of cancer occur 
much more frequently in PD patients compared with controls. Indeed, there was a 
statistically significant overall increase in the risk for cancer in both men and 
women for breast cancer, malignant melanoma, brain cancer and other types of 
skin cancers (Fig. 1.10) (Olsen et al., 2005). Thus, although it is attractive to 
speculate that a specific genetic background that predispose an individual to 
neurodegeneration in PD can protect the same individual from cancer, it may also 
be true in some cases that certain PD-linked genes when dysfunctional may trigger 
cell death in post-mitotic neurons and paradoxically also promote de-regulated 
proliferation in dividing somatic cells. It has become increasingly clear recently 
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1.10 Parkin 
 Parkin is a 52kDa E3 ubiquitin ligase whose mutations were originally 
linked to autosomal recessive juvenile parkinsonism (ARJP) (Kitada et al., 1998), 
an inherited form of PD that usually afflicts individuals before 40 years of age. 
The parkin gene was assigned the PARK2 locus in the original report and 
thereafter. Accordingly, much of the interest in characterizing the function of the 
parkin gene has been directed towards understanding its role in PD 
neurodegeneration. However, aberrant parkin function has also been linked to 
several other disorders like leprosy (Mira et al., 2004) and transient focal cerebral 
ischemia (Mengesdorf et al., 2002), amongst which, to the development of several 
types of cancers (Cesari et al., 2003). Comparatively, the role of parkin in these 
disorders is less well characterized. Here, I shall provide a brief overview of our 
current understanding of parkin function and its rather unexpected role in cancer. 
 
1.10.1 Genetic Organization and Regulation of Parkin 
 The parkin gene (also known as PARK2) spans an impressive length of 
1.43 Mb on human chromosome 6. It contains 12 exons that are each flanked by 
introns of massive size averaging 100 kb each. Not surprisingly, parkin is one of 
the largest human gene after dystrophin in the human genome. Parkin shares a 
common 204 bp bidirectional promoter with an adjacent gene, PACRG which 
spans a genomic size of only about 0.6 Mb and contains about 5 exons encoding a 
protein of about 257 amino acids. Perhaps because of its enormous gene size that 
is accompanied by a paradoxically tiny upstream region, the regulatory elements 
of parkin remains relatively poorly understood although several studies have 
indicated that parkin can be regulated under a variety of conditions. N-myc, a 
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transcription factor involved in neuronal development has been shown to be able 
to bind to the parkin promoter and negatively regulate parkin through reduction of 
its promoter activity (West et al., 2004b). Supporting this, several high N-myc 
expressing neuroblastoma cell lines are characterized by low levels of parkin 
(West et al., 2004b). Like the action of N-myc, the presence of biallelic 
hypermethylation on CpG island positions in the promoter region of parkin also 
leads to the downregulation of parkin transcript levels as evident in acute 
lymphoblastic leukemia and chronic myeloid leukemia patients (Agirre et al., 
2006).  
 
1.10.2 Distribution and Expression of Parkin 
 Parkin is ubiquitously expressed and distributed in a wide range of organs, 
tissues and glands which include the brain, heart, skeletal muscles, stomach, 
colon, kidney, testis, ovary, thyroid and adrenal glands with a much higher 
expression level in the heart and the skeletal muscles (Kitada et al., 1998). In the 
brain, the expression of parkin is not solely confined to the SNpc but also present 
in many other regions such as the cerebral cortex, cerebellum, thalamus, 
amygdala, corpus callosum, hippocampus and subthalamic nucleus. (Kitada et al., 
1998). At the cellular level, parkin is usually uniformly localized throughout the 
cytosol and can be found in the endoplasmic reticulum, Golgi apparatus and 
mitochondrial membrane.  Although the nucleus was thought to be devoid of 
parkin, recent evidence suggests that parkin may translocate to the nucleus under 
certain conditions. For example, Kao showed that parkin translocates to the 
nucleus following DNA damage (Kao, 2009a), apparently to assist in DNA repair 
(Kao, 2009b). In a separate study, de Costa and colleagues demonstrated that 
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endogenous parkin could regulate p53 expression in the nucleus of mammalian 
cell (Alves da Costa et al., 2009). However, since parkin lacks a defined nucleus 
localization signal, precisely how the translocation of parkin occurs under 
different conditions remains to be elucidated. 
 
1.10.3 Structure and Function of Parkin 
 Structurally, the 465 amino acid-containing parkin protein is composed of 
several modular domains. At the N-terminal of parkin, there is an UBL (ubiquitin-
like) domain, a unique central sequence connecting the UBL to the two RING 
(Really-Interesting-New-Gene) finger domains (Fig. 1.3) (Shimura et al., 2000). 
The two RING finger domains (RING1 and RING2) are further separated by a 
cysteine-rich IBR (In-Between-Ring) domain. Together, the RING-IBR-RING 
domain constitutes the catalytic box of parkin. However, the RING2 domain 
appears to be the essential domain for parkin’s catalytic activity as the majority of 
the missense mutations that occur on outside parkin’s RING2 domain retain much 
of their catalytic activity (Wang et al., 2005, Sriram et al., 2005, Matsuda et al., 
2006). Recently, a region on parkin which resides between the UBL and RING1 
domains of parkin was proposed to contain a new RING domain (designated 
RING0). Like RING1 and 2, RING0 was found to co-ordinate Zn2+ ion and this 
property of RING0 is apparently important in maintaining the three-dimensional 
structure of parkin and thereby its enzymatic activity (Hristova et al., 2009). The 
UBL domain shares 60% homology to ubiquitin (Kitada et al 1998) and was 
demonstrated to bind to Rpn10, a subunit of the 26S proteasome which could 
serve to target K48 polyubiquitinated substrates of parkin to the 26S proteasome 
for degradation (Sakata et al., 2003). 
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 Soon after the discovery of parkin as a PD-linked gene, several groups 
showed that parkin-mediated ubiquitination is linked to protein degradation and 
that disease-associated parkin mutations compromise its E3 ligase activity (Imai et 
al., 2000, Zhang et al. 2000, Shimura et al., 2000). However, it is now clear that 
parkin is a unique, multifunctional enzyme that is capable of performing multiple 
forms of ubiquitin modifications including monoubiquitination and lysine 63 
(K63) polyubiquitination (Tan et al., 2007; Moore 2006). Notably, both 
monoubiquitination and K63-linked polyubiquitination are typically uncoupled 
from the proteasome and are often considered as “non-proteolytic” in nature (Lim 
et al., 2005, Hampe et al., 2006, Matsuda et al., 2006). Instead, both forms of 
ubiquitin modification by parkin may participate in cellular signaling. Supporting 
this, Fallon and colleagues demonstrated that parkin-mediated monoubiquitination 
of the adaptor protein Eps15 inhibits its ability to initiate receptor down-regulation 
and leads to enhanced EGF receptor signaling as well as downstream EGF-
induced Akt signaling (Fallon et al., 2006). Separately, parkin-mediated K63-
linked ubiquitination was proposed by our lab to be involved in cargo diversion 
during proteasomal stress and accordingly, in the biogenesis of inclusion bodies 
associated with various neurodegenerative diseases (Lim 2006). Consistent with 
this, our lab and others have shown that parkin-mediated K63 polyubiquitination 
of proteins (synphilin-1 and misfolded DJ-1) promotes their sequestration to 
aggresome-like inclusion bodies (Lim et al., 2005, Olzmann et al 2007). Related 
to this, our lab has also identified K63-linked polyubiquitin as a novel cargo 
selection signal for macroautophagy-mediated clearance of aggresomes (Tan et 
al., 2008, Tan et al., 2008 Autophagy). Thus, parkin appears to be capable of 
performing multiple roles in the cell. 
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1.10.4 Mutations in Parkin 
Mutations in parkin were originally identified in Japan more than a decade 
ago to be causative of ARJP (Kitada et al., 1998). Following this discovery, 
several ethnically diverse individuals with early-onset PD (age < 45 years) in 
other parts of the world were also found to carry parkin mutations, which occur at 
a frequency of about 10-20% and 50% in sporadic and familial early-onset cases 
respectively (Lucking et al., 2000; Mata et al., 2004; Periquet et al., 2003). To 
date, more than 100 different parkin mutations have been described with over 50 
of these being missense/nonsense substitutions (Fig. 1.11). Although most of the 
missense mutations occur within the RING1-IBR-RING2 catalytic moiety, many 
of them are also found along the length of the protein outside this region. Further, 
exonic mutations are also frequently observed with deletion of exon 3 and/or 4 
being the most common (Hedrich et al., 2004). Notwithstanding the heterogeneity, 
there is no observable difference in the clinical signs and symptoms among PD 
patients carrying different parkin mutations.  The probability of having a parkin 
mutation correlates inversely with age and is likely to be as high as 50% in 
patients with parkinsonism less than 25 years of age (Lücking et al., 2000). A 
large proportion of the missense parkin mutations are attributed to a common 
founder whereas exon rearrangements like deletions and duplications tends to be 
de novo (Lincoln et al., 2003). 




Figure 1.11 Parkin exon structure and various mutations. Parkin protein structure 
and indication of the various domains including UBL, RING1, IBR and RING2 (upper 
panel). Various PD-linked parkin muations which included micro-insertions, exon 
deletions, duplications and multiplications on various regions located on parkin exons 
(lower panel) (Image from Tay et al., 2011).  
 
The mutations found in parkin were originally thought to abolish its 
catalytic properties, but several studies have showed that many disease-associated 
parkin mutants still preserve significant ubiquitination activity (Zhang et al., 2000, 
Imai et al., 2000). Instead, misfolding of parkin triggered by these mutations 
appears to be the major mechanism underlying parkin inactivation. Notably, 
missense parkin mutations frequently alter the protein solubility and 
concomitantly promote its aggregation into inclusion bodies (Ardley et al., 2003; 
Cookson et al., 2003; Gu et al., 2003; Hampe et al., 2006; Muqit et al., 2004; 
Sriram et al., 2005; Wang et al., 2005b) These missense mutations in parkin seem 
to inactivate parkin’s activity through altering the protein’s solubility and 
concomitantly promote its aggregation into inclusion bodies (Wang et al, 2005). 
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Other mutations of parkin compromise its function by destabilizing the protein 
and increase its rate of degradation via the proteasome (Schlehe et al., 2008). 
 
1.11 Parkin and Cancer 
 Although a role for parkin in cancers may come as a surprise to many, the 
1.4Mb parkin gene is located within the common fragile site (CFS), FRA6E, a 
mutational hotspot on chromosome 6 that is frequently deleted in several tumor 
types including breast, ovarian, kidney and liver cancers (Smith 1998). Indeed, 
parkin bears genomic similarities to two other large tumor-suppressor genes that 
also resides within CFS regions FHIT/FRA3B (Druck et al., 1998) and 
WWOX/FRA16D (Bednarek et al., 2001). In a recent study, parkin was found to 
be frequently affected by homozygous and hemizygous deletions (Fig. 1.12) 
(Bignell et al., 2010). In a related study, high-resolution analyses of somatic copy-
number alterations (SCNAs) from 3,131 cancer specimens comprising of 26 
histological types revealed that parkin (PARK2) is frequently deleted in a variety 
of cancer cell types (Fig. 1.13) (Beroukhim et al., 2010). 
 
Figure 1.12 Genomic Deletion Profile of human chromosome 6 from a panel of 
746 cancer cell lines. Homozygous deletions are indicated in red and hemizygous 
deletions are indicated in blue. Each tick-mark on the vertical axis denotes ten deletions 
and the horizontal axis represents p-telomere to q-telomere. (Image from Bignell et al., 
2010) 
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Figure 1.13  The Identification of significant arm-level and focal SCNAs across the 
panel of cancers. Deletions are in blue and amplifications of the respective genes are in 
red. Parkin is denoted by PARK2. (Image from Beroukhim et al., 2010)                                                                
 
Further to this, parkin gene alterations and expression variability were 
discovered in a variety of tumor biopsies and cell lines representing a wide range 
of cancers including ovarian (Denison et al., 2003), breast (Cesari et al., 2003), 
lung (Picchio et al., 2004), liver (Wang et al., 2004), colorectal (Ikeuchi et al., 
2009) (Poulogiannis et al., 2010) cancers, lymphomas (Gaidano et al., 1992), 
melanomas (Millikin et al., 1991; Guan et al., 2002) and leukemias (Agirre et al., 
2006). There is frequent diminished or absence of parkin expression in these 
cancers which implicate parkin as a putative tumor suppressor. Supporting this, 
microcell-mediated transfer of human chromosome 6 (where parkin resides) into 2 
breast cancer cell lines (Negrini et al., 1994) and BKV-transformed mouse 
pRPcT1ss1 cells (Gualandi et al., 1994) result in reduced tumorigenicity and 
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restoration of the ability of these cells to undergo senescence. Further evidence 
supporting a tumor suppressor role for parkin came from a parkin null mice 
model, which exhibit enhanced hepatocyte proliferation and development of 
macroscopic hepatic tumors with the characteristics of hepatocellular carcinoma 
(Fujiwara et al., 2008). Mechanistically, how does parkin dysfunction contribute 
to cancer remain relatively not well understood, although the accumulation of 
certain substrates in the absence of functional parkin expression may hold the key 
to unlock the pathways involved. 
 
1.12 Cyclin E – A link between parkin, cancer and neurodegeneration? 
Among the laundry list of parkin substrates or putative substrates that has 
been identified to date (Table 2), the cell cycle regulator cyclin E is perhaps the 
most relevant one in connecting parkin function to cancer.  




Table 2 List of parkin substrates/ putative substrates (Adapted from Tay et al., 2011) 
 
The elucidation of cyclin E, an interactor of hSel-10, as a parkin 
degradation-associated substrate led to the proposal that parkin may operate as 
part of a multiprotein ubiquitin ligase complex that comprises also of Cullin 
(Staropoli et al., 2003). As discussed above, ubiquitination and degradation of 
phosphorylated cyclin E by the SCFhSel-10 complex underlies the regulation of cell 
cycle entry into S phase. Accordingly, accumulation of cyclin E upon parkin 
dysfunction could promote aberrant cellular proliferation. Supporting this, recent 
studies have demonstrated defects in cyclin E proteolysis in colon and brain 
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cancer cells harboring dysfunctional parkin (Ikeuchi et al., 2009, Veeriah et al., 
2010). In postmitotic neurons, cyclins accumulation has been implicated in 
triggering apoptosis. Not surprisingly, the regulation of cyclin E levels by parkin 
has apparent effects on cellular apoptosis. Primary neuronal cultures rendered 
deficient in parkin by RNA interference displayed increased accumulation of 
cyclin E that correlates with increased cleaved poly (ADP-ribose) polymerase, a 
marker of apoptosis. Furthermore, cyclin E also accumulates in SN extracts from 
parkin-deficient PD brains, suggesting its involvement in PD pathogenesis 
(Staropoli et al., 2003). It is therefore attractive to suggest that altered cyclin E 
proteolysis in parkin-deficient cancer and neuronal cells may underlie their 
respective susceptibility to undergo cell division and degeneration. However, a 
caveat is that parkin-cyclin E relationship is not universally observed (Tay et al., 
2010).  
Interestingly, parkin also exhibits an apparent E3-independent function in 
the control of gene transcription. Amongst the genes regulated by parkin is the 
p53 tumor suppressor, whose expression is repressed by functional parkin (Alves 
da Costa et al., 2009). This is rather surprising, as the elevation of p53 levels in 
parkin-deficient cells should in theory retard (instead of promote) cell division. 
Other genes whose expression is also regulated by parkin are follistatin, CDK6 
and Eg5. Whereas the level of follistatin increases in parkin-deficient cells, the 
reverse is true for CDK6 (Fujiwara et al., 2008, Tay et el., 2010). Both events are 
however thought to promote carcinogenesis (Fujiwara et al., 2008, Tay et el., 
2010). Accumulation of Eg5, a member of the kinesin family, can lead to genome 
instability in transgenic mice and is associated with leukemia (Liu et al., 2008). 
Liu and colleagues demonstrated that parkin represses the expression of Eg5 via 
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inactivation of JNK signaling pathway, suggesting a novel mechanism by which 
parkin can exert its tumor suppressor function (Liu et al., 2008). 
 
1.13 Other PD-linked Genes and Cancer 
 Although my thesis topic is primarily focused on the role of parkin in 
gliomagenesis, it is noteworthy to highlight that besides parkin, there are at least 4 
other PD-linked that are suspected to also play a role in cancer development 
namely α-synuclein, PINK1, DJ-1 and LRRK2 (Table 3), which I will briefly 
discuss below. 





























Table 3. Genetic Determinants at the interface of neurodegeneration and cancer. 
(Adapted from Plun-Favreau et al., 2010) 
 
α-synuclein is a small (140 amino acid) presynaptically-enriched protein of 
largely unknown function. Like parkin, mutations of α-synuclein, which can occur 
as substitution (A53T, A30P and E46K) or gene duplication/triplication, were 
originally associated with familial parkinsonism (Kumar et al., 2009). More 
recently, α-synuclein was shown to be highly expressed in human melanoma cell 
lines but is undetectable in non-melanoma cell lines, suggesting a potential link 
between abnormal α-synuclein expression and skin cancer.  Specifically, α-
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synuclein was positively detected in 86% of the primary and 85% of the 
metastatic melanoma sections and was undetectable in non-melanocytic cutaneous 
carcinoma and normal skin (Matsuo et al., 2010). 
PINK1 is a 581 mitochondrial-localized serine/threonine kinase whose 
mutations cause autosomal recessive PD. PINK1 is otherwise known as PTEN-
Induced Kinase, which immediately suggest its relationship with the tumor 
suppressor and hence cancer. Indeed, the restoration of PTEN in PTEN-deficient 
cancer cells enhanced the expression of PINK1 indicating its regulation by PTEN. 
(Matsushima-Nishiu et al., 2001). By virtue of its positive association with PTEN, 
it is attractive to speculate that PINK1 may have a tumor suppressing role. 
Unlike most other PD-linked genes, DJ-1 was originally identified as a 
novel oncogene with the ability of transforming mouse NIH3T3 cells in 
cooperation with H-ras (Nagakubo et al., 1997). The downregulation of DJ-1 
using siRNA was observed to enhance apoptosis by oxidative stress, proteasome 
inhibition and endoplasmic reticulum stress (Yokota et al., 2003). Importantly, 
DJ-1 deficiency results in decreased phosphorylation of Akt, whereas its 
overexpression leads to Akt hyperphosphorylation and increased cellular 
proliferation. In primary breast cancer samples, DJ-1 expression correlates 
negatively with PTEN immunoreactivity and positively with Akt 
hyperphosphorylation which implicates DJ-1 as a negative regulator of the tumor 
suppressor, PTEN (Kim et al., 2005). More recently, DJ-1 was found to enhance 
cell survival through interaction with cezanne, a deubiquitination enzyme that 
inhibits NF-κB activity and further microarray profiling revealed that DJ-1 and 
Cezanne could regulate IL-8 and ICAM-1 expression (McNally et al., 2010). In 
another study, elevated levels of circulating DJ-1 and anti-DJ-1 autoantibodies 
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have been detected in breast cancer patients as compared to normal healthy 
control individuals (Le Naour et al., 2001). All these evidences support DJ-1 
function as an oncogene. 
 LRRK2 is a 2527 amino acid large GTP-regulated serine/threonine kinase 
consisting of several structural and functional domains which include ankyrin 
repeat region (ANK), leucine-rich repeat domain (LRR), Ras of complex proteins 
domain (ROC), COR (carboxy terminal of ROC) domain, kinase domain 
(consisting of mitogen activated protein kinase kinase kinase) and WD40 domain. 
Structurally, it is apparent that LRRK2 contain many motifs that are typically 
involved in mitogenic signaling. LRRK2 apparently interacts with the C-terminal 
RING2 finger domain of parkin through the COR domain (Smith et al., 2005). 
Currently, mutations of LRRK2 are presumed to cause PD through a toxic gain of 
function mechanism that elevates its kinase activity. For example, several disease-
associated LRRK2 mutations such as G2019S and I2020T exhibit enhanced 
kinase activity (Moore, 2008). A recent study showed that there is an increased 
risk of non-skin cancers in LRRK2 G2019S mutation carriers, which may be 
related to toxic gain of function of mutated LRRK2 (Saunders-Pullman et al., 
2010). LRRK2 was amplified and overexpressed in papillary renal and thyroid 
carcinomas, subsequent downregulation of LRRK2 in cultured papillary renal and 
thyroid carcinoma cells was observed to compromise MET activation and 
selectively reduces downstream MET signaling of mTOR and STAT3 (Looyenga 
et al., 2011). This would eventually lead to the loss of important mitogenic 
pathways which induces cell cycle arrest and cell death due to loss of ATP 
production. Thus, MET and LRRK2 could potentially cooperate to promote 
efficient cancer cell growth and proliferation.  
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1.15 A role for parkin in gliomagenesis – Project Aims and Rationales 
At the start of my project, a definite role for parkin in gliomagenesis has 
yet to be established, let alone the mechanism underlying the potential effects of 
parkin on glioma growth. Given the importance in understanding the molecular 
mechanism underlying the formation of glial tumors, I was interested to pursue 
this novel topic. Furthermore, brain cancer is one of the few cancer types that are 
over-represented in the PD population. One of the first questions that I have 
therefore asked myself was if there were any evidence at all that might implicate 
the involvement of parkin in gliomagenesis. Shortly after my project has started 
formally, I found a paper by Mulholland and colleagues who showed by means of 
high resolution microarray comparative genomic hybridization and molecular 
cytogenetic characterization techniques that parkin was deleted in 2 out of 10 
GBM patients’ tumor samples and 4 out of 10 glioblastoma cell lines (Mulholland 
et al., 2006). The finding by Mulholland et al has given me some confidence that I 
was not on a wrong track altogether. Along the way, I have gathered increasing 
evidence that supports the involvement of parkin in gliomagenesis. Moreover, a 
related paper by McLendon and colleagues was published who demonstrated in 
three microarray platforms (each analyzed with multiple analytical algorithms) 
that significantly recurrent focal alterations involving homozygous deletions of 
parkin were detected in 206 glioblastomas (McLendon et al., 2008). Together, the 
reported findings as well as my own findings suggest that parkin acts as a putative 
tumor suppressor gene in gliomagenesis. My project directions therefore become 
progressively clearer during the course of my Ph.D. work and I found myself 
probing deeper and deeper into the topic.  
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In sum, the chronological objectives (with the benefit of hindsight) 
regarding the role of parkin in gliomagenesis that I have pursued during the course 
of my Ph.D. work can be summarized as follows: 
 
I. To characterize the expression of parkin in glioma cells and examine the 
effects of parkin over-expression on the rate of glioma cell proliferation 
both in vitro and in vivo. 
II. To dissect the mechanism underlying parkin-mediated tumor suppression 
(of glioma growth). 
III. To validate the results obtained (from above aims) in human biopsy 
samples and/or glioma databases. 
 
At the end of my Ph.D. work, I was able to make the following discoveries 
regarding the role of parkin in gliomagenesis, which I believe are of significance. 
 
1. Firstly, I have found that parkin expression is highly deficient in glioma cells 
both at the transcript and protein level. By means of both in vitro cancer cell 
assays and an intracranial glioma in vivo model. I demonstrated that restoration 
of parkin expression in parkin-deficient glioma cells significantly mitigates 
their growth 
 
2.  I found that parkin expression in otherwise parkin-deficient glioma cells 
promote their arrest at the G1 cell cycle phase and have identified cyclin D1 
and Akt signaling as key factors regulated by parkin that influence cell cycle 
progression in glioma cells.  
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3. Finally, with help from an in-house bioinformatician, I have identified a 
signature pathway of parkin as an independent predictor of glioma disease 
progression and survival that predicted survival outcome in glioma patients 
better than histology alone. My findings here therefore have potential 
prognostic value. 
 
Taken together, the main finding of my thesis work is that parkin pathway 














The FLAG-tagged parkin expression construct was a kind gift from 
Professor R. Takahashi (Kyoto University). The FLAG-tagged T415N 
catalytically null parkin mutant was constructed through site-directed mutagenesis 
by means of the QuickChangeTM method (Stratagene, La Jolla, CA, USA) as 
previously described by our lab (Wang et al., 2005). 
 
2.1.2 Antibodies 
The following antibodies were used: mouse monoclonal anti-β-actin 
(Sigma), rhodamine-conjugated anti-mouse and anti-rabbit IgG (Molecular 
Probes, Eugene, OR, USA), fluorescein-conjugated anti-mouse IgG (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA), fluorescein-conjugated 
anti-rabbitIgG (BD Biosciences), mouse monoclonal anti-parkin (clone PRK8) 
(Covance), phospho-Akt (Ser 473) (Cell Signaling, USA), phospho-Akt (Thr 308) 
(Cell Signaling, USA), phospho-PDK1 (Cell Signaling, USA), PDK1 (Cell 
Signaling, USA), Akt (Cell Signaling, USA), cyclin D1 (Cell Signaling, USA), 
Hsp70 (BD Biosciences Pharmingen, USA), Hsp90 (BD Transduction 
Laboratories, USA). 
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2.1.3 Cell lines 
HEK293 cells (from ATCC, catalog no. CRL-1573), MCF7 (kind gift from 
Associate Professor Bay Boon Huat, National University of Singapore), U87MG 
(kind gift from Dr Carol Tang, National Neuroscience Institute). Immortalized 
wild type and parkin null mouse embryonic fibroblasts (derived from parkin exon 




2.2.1 Cell Culture 
Human Embryonic Kidney (HEK) 293 and MCF-7 cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% foetal bovine 
serum (FBS) supplemented with 100units/ml of penicillin/streptomycin in a 5% 
CO2 atmosphere at 37°C. The various glioma cell lines used in the study, i.e. U-
87MG, U-373MG, U-251MG, A-172 and T-98G cells were also grown in DMEM 
containing 10% FBS containing  supplemented with 100units/ml of 
penicillin/streptomycin, but including 0.1mM MEM non-essential amino acids 
(Invitrogen, USA) and 1mM MEM sodium pyruvate (Invitrogen, USA) in a 5% 
CO2 atmosphere at 37°C. Primary mouse embryonic fibroblasts (MEFs) (see 
section below for preparation) were maintained in DMEM containing 10% FBS 
supplemented with 100units/ml of penicillin/streptomycin, 2mM glutamine and 
55µM β-Mercaptoethanol in a 5% CO2 atmosphere at 37°C. The cells were 
maintained on round 10-cm tissue culture plates (Corning, USA) and were 
passaged every two to three days or whenever they are confluent in a 5% CO2 
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atmosphere at 37°C. Generally, primary MEFs at low passage number (between 2-
4) were used for analysis. 
 
2.2.2 Preparation of primary MEFs 
From wild type and parkin KO mice, the fetuses were extracted from 
embryonic day 14 were removed and place in a sterile 10-cm tissue culture plate 
(Corning, USA) containing 1x PBS. The head, spinal cord and the internal organs 
of the fetus was removed and the remaining body parts were dissected into fine 
pieces. The pieces were transferred to a centrifuge tube containing 12ml of trypsin 
and were stored at 4oC overnight. The next day, the centrifuge tube containing the 
embryonic parts were incubated at 37oC for 15 minutes and were vigorously 
titrated with 8ml of MEF medium before the supernatant was collected and the 
cells pelleted at 1,000 rpm for 5 minutes. The supernatant was discarded and the 
cell pellet was resuspended in MEF medium before it was plated out onto 10-cm 
tissue culture plate. 
 
2.2.3 Cryopreservation of cells 
The cultured cells were cryopreserved in cryopreservation medium 
containing 50% FBS, 40% DMEM and 10% dimethyl sulfoxide (DMSO) for 
long-term storage in liquid nitrogen. The cells were trypsinized using 2ml of 
trypsin for one to two minutes before the equal volume of culture medium was 
added to it to stop trypsin activity. The cells were then transferred into a 15ml 
centrifuge tube and spun at 1,000 rpm for 5 minutes. The supernatant was then 
removed and the cell pellet was resuspended in an appropriate volume of 
cryopreservation medium at 4oC to make up to a concentration of 1 x 106 cells/ml 
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in cryovials. The cryovials were then left in -20oC for 2 hours before it is 
transferred to -80oC for overnight and finally transferred to liquid nitrogen the 
next day. 
 
2.2.4 Thawing of cryopreserved cells 
The cryovial was quickly removed from the liquid nitrogen and thawed in 
a clean 37oC water-bath. The cryopreservation medium in the cryovial is thawed 
until there is a tiny shard of ice left before it was transferred into 9 ml of ice-cold 
DMEM or culture medium in a 15ml centrifuge tube. The centrifuge tube was 
then spun at 1,000 rpm for 5min (Eppendorf Centrifuge 5810, USA). The 
supernatant was then removed and the cell pellet was resuspended in 10ml of 
culture medium in a 10-cm tissue culture plate. The used medium in the 10-cm 
tissue culture plate was replaced with fresh culture medium on the next day to 
remove trace amount of DMSO. 
 
2.2.5 Transfection of U-87MG using Invitrogen Plus™ and lipofectamine™ 
reagents 
The required amount of plasmid was aliquoted out into a 1.0 ml 
microcentrifuge tube (0.5µg of plasmid for 6-well tissue culture plate and 1.0µg of 
plasmid for 10cm tissue culture plate) and topped up with 100µl Opti-MEM 
(Invitrogen, USA) or serum-free DMEM. 6ul of PLUS reagent (Invitrogen, USA) 
was added to the microcentrifuge tube and the tube was mixed well by pipetting 
up and down, briefly spun down and labeled as tube A. Tube A was then 
incubated at room temperature for 15 minutes. After 15 minutes of incubation at 
room temperature, tube B containing 4µl of lipofectamine topped up with 100µl of 
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Opti-MEM or serum-free DMEM were added to tube A and incubated for another 
15 minutes at room temperature. The medium from the cells in 6-well tissue 
culture plate were aspirated and replaced with 800µl of either Opti-MEM or 
serum-free DMEM medium. The transfection reagents containing the plasmid 
were added dropwise to the well and the well was swirled gently to allow even 
mixing of the transfection reagents and plasmid with the cells. The cells in the 
well were seeded at a concentration of 1x105cells/well for at least 24 hours prior 
to transfection. The transfection medium with the cells in the 6-well plate were 
incubated in a 5% CO2 atmosphere at 37°C for 4 hours before the transfection 
medium was aspirated and replaced with 3ml of fresh culture medium. The cells 
were then incubated in a 5% CO2 atmosphere at 37°C for another 48 hours for the 
episomal replication of the plasmid and expression of the protein in the cells. 
 
2.2.6 Preparation of electrocompetent cells for electroporation 
A sterile inoculating loop was used to streak out single bacteria colonies 
on a Luria-Bertani (LB) plate from a bacteria stock tube stored at -80oC and was 
incubated overnight in a 37oC bacteria incubator. The following day, a single 
bacterial colony was picked from the LB plate, inoculated into 3ml of LB broth 
and incubated overnight at 37oC, shaken at 220 rpm. The next day, the 3ml 
overnight culture of bacteria was transferred into 200ml of LB broth kept at 37oC, 
shaken at 220 rpm until it reached at OD600 of 0.8 to 0.9. The bacterial culture was 
chilled on ice for 30 minutes once it reached the desired OD600 and after this, the 
bacteria culture was aliquoted into a clean telfon centrifuge tube and spun at 4,000 
rpm for 15 minutes at 4oC with the supernatant decanted after centrifugation. The 
bacterial cell pellet was thoroughly resuspended in 200ml of sterile, ice-cold 10% 
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glycerol and spun at 4,000 rpm for 15 minutes at 4oC with the supernatant 
decanted after centrifugation. The bacterial cell pellet was further resuspended in a 
lesser volume of 100ml of sterile, ice-cold 10% glycerol and again spun at 4,000 
rpm for 15 minutes at 4oC with the supernatant decanted after centrifugation. The 
remaining bacterial cell pellet was resuspended in 10ml of sterile, ice-cold 10% 
glycerol before it was transferred into a 50ml centrifuge tube. The bacterial cells 
were centrifuged at 3,500 rpm for 15 minutes at 4oC with the supernatant removed 
after centrifugation. Finally, the bacterial cell pellet was resuspended in 1ml of 
sterile, ice-cold 10% glycerol before it was aliquoted in volumes of 50µl into each 
microcentrifuge tube and stored at -80oC prior to use. 
 
2.2.7 Electroporation of electrocompetent cells 
0.1µg of desired plasmid was added into a tube of freshly thawed out 
electrocompetent cells and mixed thoroughly before it was transferred into a 
sterile electroporation curvette that was pre-chilled on ice. The electroporation 
curvette was gently tapped a few times to bring the competent cells down to the 
bottom of the tube and was then placed into the electroporation machine (Bio-
Rad, USA). The bacterial cells were then electroporated according to the 
manufacturer’s instructions on the electroporation machine (Bio-Rad, USA) at 
2.5kV. After the electroporation step, 1ml of sterile LB broth was added into the 
curvette and mixed thoroughly after which it was then pipetted out and transferred 
into a bacterial culture tube and shaken at 220rpm, 37oC for an hour for the 
recovery of the electroporated bacterial cells. After the incubation, 20µl of the 
bacterial culture was plated onto a LB agar plate with ampicillin and the plate was 
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incubated overnight in a bacterial incubator at 37oC for isolation of single 
colonies. 
 
2.2.8 Extraction of plasmid 
For mini-plasmid preparation, a single plasmid-containing bacteria colony 
was inoculated into 3ml of LB broth in a bacterial culture tube and was incubated 
at 37oC, 220 rpm overnight. plasmid was extracted using the Axygen plasmid 
miniprep kit according to the manufacturer’s instructions. For the preparation of 
larger amount of plasmid, the Invitrogen plasmid maxiprep kit was used. In this 
case, the overnight 3ml bacteria culture was added into 400ml of LB broth and 
was allowed to grow at 37oC, 220 rpm for another 24 hours.  
 
2.2.9 Creation of vector control, human wild type parkin and mutant 
parkin, T415N stables in U-87MG glioma cell line 
The cells were first transfected with the relevant plasmids (empty 
pCDNA3 plasmid vector, pCDNA3-FLAG- wild type parkin, pCDNA3-T415N 
mutant parkin) using the Invitrogen PlusTM and lipofectamineTM reagent 
transfection protocol and the cells were then incubated in a 5% CO2 atmosphere at 
37°C for 48 hours. Transfected cells were then harvested using trypsinization and 
re-seeded at a concentration of 1 x 105 cells into each round 10-cm tissue culture 
plates. After 24 hours in culture, the used culture medium was replaced with fresh 
culture medium containing 1000µg/ml of geneticin (G418). Before this, a kill 
curve was established for U-87MG cell line using various concentration of 
geneticin (0µg/ml, 200µg/ml, 400µg/ml, 600µg/ml, 800µg/ml, 1000µg/ml) and 
the optimum concentration of geneticin (i.e. 1000µg/ml) was determined as the 
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concentration that was able to kill off 95-100% of the cells on the day 05 of the 
culture. The cells were incubated in a 5% CO2 atmosphere at 37°C for 5 days to 
allow for the isolation of single cells that contained the desired transfected 
plasmid in them. The concentration of geneticin in the culture medium was then 
lowered to 200µg/ml and sterile cloning cylinders (Sigma, USA) were placed 
around each isolated single cells after 5 days to allow for the formation of single 
colonies on the 10-cm tissue culture plate. After 2-3 weeks, the colonies formed 
were picked off from the 10-cm tissue culture plate using 15µl of 37°C pre-warm 
trypsin in a yellow pipette tip pipetted up and down vigorously for 20-30 times in 
order to allow the colonies to be dislodged from the plate. The picked colonies 
were then transferred into a 96-well flat-bottomed tissue culture plate with each 
well containing 200µl of culture medium. The cells were monitored daily for 
confluency and were transferred to a 24-well tissue culture plate upon reaching 
confluency. The confluent cells in the 24-well tissue culture plate were then 
transferred into 6-well tissue culture plate and upon reaching its confluency, they 
were sub-divided into two 6-well tissue culture plates, one was used for the 
checking of expression using parkin monoclonal antibodies (prk8 clone) in 
immunoblotting and the other for the maintenance in passage. Once the 
identification of the positive clones have been established at least 3 times, the 
parkin-positive cells were expanded in 10-cm tissue culture plates and a 
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2.2.10 Total RNA extraction using Qiagen RNeasy® Mini Kit (Qiagen, 
Singapore) 
U-87MG cells were grown on 10-cm tissue culture plate 24 hours prior to 
the harvesting of total RNA. The culture medium was aspirated from each 10-cm 
tissue culture plate and the plates were washed once with ice-cold PBS, pH 7.4 
before 600µl of Buffer RLT containing β-Mercaptoethanol was added to the plate 
and the cells on the plate were lysed and scraped using a cell scraper. The lysate 
was then transferred to a RNase-free 1.5ml microcentrifuge tube and was 
subsequently homogenized by passing the lysate through a 23G gauge needle 10 
times using a RNase-free 1.0ml syringe. The lysate was then centrifuged in a 
microcentrifuge at 13,000 rpm for 3 minutes before the supernatant was removed 
and transferred to a new 1.5ml microcentrifuge tube. 600µl of 70% ethanol was 
added to the supernatant and was mixed immediately by pipetting up and down 
for a 5 times before the mixture was transferred to a RNeasy spin column placed 
in a 2ml collection tube and was spun at 13,000 rpm for 15 seconds. The 
flowthrough was discarded and following after this, 700µl of Buffer RW1 was 
added to the spin column and centrifuged at 13,000 rpm for 15 seconds. After the 
flowthrough was removed, 500µl of Buffer RPE was added into the spin column 
and centrifuged at 13,000 rpm for 2 minutes. The procedure was repeated again 
before the RNeasy spin column was placed in a new 1.5ml microcentrifuge tube. 
40µl of pre-warmed RNase-free water was added to the centre of the RNeasy spin 
column and centrifuged at 13,000 rpm for 1 minute to elute out the RNA. The 
concentration of total RNA was determined by using the NanoDrop ND-1000 
machine (Thermo Scientific, USA). 
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2.2.11 Reverse-transcription of total RNA using Invitrogen SuperScript™ II 
Reverse Transcriptase 
15µg of total RNA, 3µl of random primers, 3µl of dNTP mix (10mM 
each) were added into a nuclease-free microcentrifuge tube and sterile, nanopure 
water was added to top up the volume to 36µl. The  mixture was heated to 65oC 
for 5 minutes and chilled on ice before the addition of 12µl of 5X First-Strand 
Buffer, 6µl of 0.1M dithiothreitol (DTT) and 3µl of RNaseOUT (40units/µl) to 
make up the volume to 57µl. The contents of the tube were mixed gently before it 
was incubated at 25oC for 2 minutes. After the incubation, 3µl of SuperScript™ II 
reverse transcriptase was added into the tube before the tube was incubated at 
25oC for 10 minutes followed by 42oC for 50 minutes and heat inactivated at 70oC 
for 15 minutes. 
 
2.2.12 Real-Time Polymerase Chain Reaction (Real-Time PCR) 
After total RNA were extracted from various glioma cells, 100ng of the 
cDNA reverse transcribed from the RNA was used for each Real-Time PCR 
reaction. The Real-Time PCR reaction was performed in a Light Cycler (Roche) 
using the FastStart DNA Master Plus Sybergreen I system (Roche, USA) 
according to manufacturer’s protocol. The primers were designed specific to our 
genes of interest were generated as follows: parkin-specific primers (Forward: 5’- 
GGAAGTCCAGCAGGTAGATCA; Reverse: 5’-ACCCTGGGTCAAGGTGAG), 
Concurrently, Real-Time PCR with a primer pair specific to GAPDH (Forward: 
5’- GAAGGTGAAGGTCGGAGTCAACG; Reverse: 5’- 
TGCCATGGGTGGAATCATATTGG) was also included in the same set of 
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experiments as a housekeeping gene. The evaluation of statistical significance was 
done using Student’s paired t-test for all comparisons (*P < 0.05, **P < 0.01). 
The Real-Time PCR cycling parameters are as followed: 
Pre-incubation Step: 95C, 10 minutes, temperature transition rate 20C/second 
Amplification Step:  95C, 10 seconds, 20C/second   } 
    60C, 10 seconds, 20C/second   } 40 
cycles 
    72C, 5 seconds, 20C/second, Single acquisition } 
Melting curve Step: 95C, 0 second, 20C/second 
    65C, 15 seconds, 20C/second 
    95C, 0 second, 0.10C/second, Continuous acquisition 
Cooling Step:  40C, 30 second, 20C/second 
The specificity of the transcript amplification for Real-time PCR was determined 
through presence of a single peak on the melt curve analysis and a single, specific 
band seen from the separation of Real-time PCR product on an agarose gel 
electrophoresis. 
 
2.2.13 Assessment of cellular proliferation using simple cell count by 
haemocytometer 
2 x 104 cells in 3 ml of culture medium were seeded into each well of a 6-
well tissue culture plate in 5 sets of triplicates. The cells were incubated in a 
humidified, 37oC, 5.0% CO2 atmosphere incubator and were harvested daily by 
means of trypsinization using 0.5ml of trypsin on each well. The various cells 
were harvested and resuspended in an appropriate volume of culture medium and 
their cell number were determined using the haemocytometer and the formula: 
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{[(A+B+C+D)] / 4}x dilution factor x 104 cells per ml, where A, B, C, D is the 
number of cells in each of the 16 squares quadrant and their numbers need to fall 
within the range of 7-70 cells for an accurate estimation of the concentration of 
cells. The number of the various cell types were determined daily and statistical 
significance was done using Student’s paired t-test for all comparisons (*P < 0.05, 
**P < 0.01). 
 
2.2.14 Assessment of cellular proliferation using Roche Cell proliferation Kit 
I (MTT) 
1 x 104 cells in 100µl of culture medium were seeded into each well of a 
flat-bottomed 96-well tissue culture plate in 5 sets of triplicates. The cells were 
incubated in a humidified, 37oC, 5.0% CO2 atmosphere incubator for 24 hours 
before 10µl of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) labeling reagent was added into each well and incubated at 37oC, 5.0% 
CO2 atmosphere incubator for 4 hours. After the 4 hours of incubation, 100µl of 
solubilization reagent was added into each well and the plate was again incubated 
in a humidified, 37oC, 5.0% CO2 atmosphere incubator for 16 hours. The 
absorbance in each well of the 96-well tissue culture plate was evaluated and 
determined with the use of an ELISA plate reader at a wavelength of 550nm and a 
reference wavelength of 690nm. The MTT assay was performed on various flat-
bottomed 96-well tissue plates daily in order to establish the rate of cellular 
proliferation over a period of 5 days. 
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2.2.15 Assessment of cellular proliferation using Roche 5-Bromo-2’-deoxy-
uridine Labeling and Detection Kit I (BrdU) 
3 x 104 of the various cell types in 1ml of culture medium were seeded into 
24-well tissue culture plate containing poly-D-lysine coated sterile 13mm round 
coverslips incubated in a humidified, 37oC, 5.0% CO2 atmosphere incubator. After 
24 hours, the cell culture medium was aspirated and replaced with fresh BrdU 
labeling medium (1:1000) and incubated at 37oC in 5.0% CO2 atmosphere for an 
hour. After incubation, the BrdU labeling medium was aspirated away and the 
coverslips were washed 3 times in the washing buffer. The cells on the coverslips 
were fixed using the designated ethanol fixative (30ml of 50mM glycine and 70ml 
of absolute ethanol, pH2.0) for 30 minutes at -20oC. After fixation, the coverslips 
were again washed 3 times in the washing buffer and 50µl of diluted anti-BrdU 
working solution (1:10 with incubation buffer) was used to cover each coverslip 
for 30 minutes at 37oC after which the coverslips were washed 3 times in the 
washing buffer. The coverslips were then covered with 50µl of anti-mouse-Ig-
fluorescein working solution (1:10 with PBS, pH7.2) for another 30 minutes at 
37oC and were counterstained with 4',6-diamidino-2-phenylindole (DAPI) for 
about 10 minutes a in moist chamber at room temperature before they were again 
washed 3 times in the washing buffer. The coverslips were then mounted onto 
glass slides using FluorSave Reagent (Calbiochem, USA). The 





Materials and Methods     67 
 
2.2.16 Soft-Agar colony formation assay 
100ml of sterile 1% agar was mixed well together with 100ml of sterile 
culture medium and was dispensed in aliquots of 3ml in each well of a 6-well 
tissue culture plate as a 0.5% agar (basal/underlay agar). The plates are allowed to 
cool and set for about 30 minutes before they are kept at 4oC for up to 2 weeks 
prior to use. The 0.5% basal agar plates are pre-warmed at 37oC in a 5.0% CO2 
incubator for 30 minutes before the start of the experiment. The cells were 
harvested by trypsinization and centrifuged at 1,000 rpm for 5 minutes. The 
supernatant was removed with the cell pellet was resuspended in an appropriate 
volume of culture medium and the concentration of cells were determined using a 
haemocytometer. 3 x 104 cells were mixed thoroughly with 3ml of cooled molten 
0.3% plating overlay agar that was previously maintained at a temperature of 42oC 
by pipetting gently up and down, taking care to avoid air bubbles. 1ml of this 
mixture was overlaid onto each 0.5% basal agar well and was allowed to cool and 
solidified. The plates were then incubated at 37oC in a 5.0% CO2 incubator for 28 
days, monitored daily under a dissecting microscope and images of their growth 
were taken every 3 days until the end of the experimental period, i.e. 28 days 
(colonies are sometimes stained with crystal violet or MTT to enhance their 
visibility). 
 
2.2.17 Cell cycle analysis via DNA content analysis using propidium iodide 
The cells were seeded at a concentration of 5 x 105cells in 10ml of culture 
medium in 10-cm tissue culture plate and incubated at 37oC in a 5.0% CO2 
incubator. After 24 hours, the culture medium was aspirated and the cells were 
rinsed 3 times with serum-free culture medium replaced with 10ml of serum-free 
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culture medium for 24 hours at 37oC in a 5.0% CO2 incubator to synchronize the 
cell cycle of the cells at G0 resting phase. After 24 hours in the serum-free culture 
medium, quiscient cells were harvested by trypsinization and the cell pellet was 
collected in a 1.5ml microcentrifuge tube. The cell pellet was resuspended in 1ml 
of 70% ethanol (for fixation) kept at -20oC for 2 hours before it was centrifuged at 
3,000 rpm for 5 minutes in a microcentrifuge. The supernatant was removed and 
the cell pellet was washed in 1ml of PBS containing 5mM 
ethylenediaminetetraacetic acid (EDTA) (divalent metal cation chelating agent to 
prevent cell to cell adhesion) before it was centrifuged again at 3,000 rpm for 5 
minutes. The supernatant was discarded and the cell pellet was resuspended in 
1ml of propidium iodide (PI)/RNase A staining solution (10ml of 0.1µg/µl of PI, 
50µl of 20mg/ml RNase A) and incubated in the dark at room temperature for 3 
hours. The cells were then analyzed by fluorescence activated cell sorting (FACS) 
at 20,000 events using DNA content analysis via histogram plot on a flow 
cytometry (Calibur) (Becton Dickinson, USA). 
 
2.2.18 Immunocytochemistry and confocal microscopy 
3 x 104 of U-87MG, U-373MG, U-251MG and T-98G cells were seeded 
onto poly-D-lysine coated sterile 13mm round coverslips in a 24-well tissue 
culture plate for at least 24 hours prior to transfection. After 48 hours post-
transfection, the cells were rinsed once with phosphate buffer saline (PBS) and 
fixed with 1.0ml of 2.5% of paraformaldehyde (w/v) at pH 7.4 for overnight at 
4oC. After the overnight fixation of the cells, they were washed three times in cold 
PBS before permeabilisation with 0.1% Triton X-100 (v/v) in PBS for 2 minutes 
at room temperature. After the permeabilisation step, 60µl of diluted anti-parkin 
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antibodies (prk8, Covance, USA) at a concentration of 0.2µg per coverslip, in 
blocking reagent which contained 5% fetal bovine serum (FBS), 1% horse serum 
and 1% bovine serum albumin (BSA) were added and incubated in a moist 
chamber overnight at 4oC. The next day, the coverslips were washed six times 
with cold PBS before incubating in secondary antibodies at a concentration 0.2ug 
per coverslip, in blocking reagent in a moist chamber for 1 hour at room 
temperature covered with aluminium foil in the dark. The secondary antibodies 
reagent was removed and the nuclei of cells were stained with 4',6-diamidino-2-
phenylindole (DAPI) for about 10 minutes a in moist chamber at room 
temperature. The glass coverslips with cells were then washed six times with cold 
PBS before the coverslips were mounted onto glass slides using FluorSave 
Reagent (Calbiochem, USA). The immunofluorescent images were then acquired 
using an Olympus confocal microscope. 
 
2.2.19 Cell lysis, western blotting and immunoblotting 
The cells were grown on 10-cm tissue culture plate before they were lysed with 
200µl of 1% triton X-100 in phosphate buffer saline (PBS) lysis buffer containing 
10μg/ml aprotinin and 1mM PMSF in PBS with phosphatase inhibitor cocktail 1 
(for inhibition of Serine/Threonine Protein Phosphatases and L-Isozymes of 
Alkaline Phosphatases) (Sigma, USA) and phosphatase inhibitor cocktail 2 (for 
inhibition of Tyrosine Protein Phosphatases, Acid and Alkaline Phosphatases) 
(Sigma, USA). The protein lysate is then transferred into a 1.5ml ultracentrifuge 
tube and centrifuged at 55,000 rpm for 15 minutes at 4oC. The supernatant was 
collected and transferred to a clean 1.5ml microcentrifuge tube and protein 
quantification was done using the Bradford assay at absorbance OD595 (Bio-Rad, 
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USA). Before the quantification of protein lysate, bovine serum albumin (BSA) of 
amount 1µg to 6µg was used to determine their respective absorbance and 
elucidate a standard curve for a range of protein concentration. 2µl of each protein 
lysate was pipetted into a disposable curvette and 1ml of diluted Coomassie® 
Brilliant Blue G-250 dye (1:4) was added into each curvette and the absorbance 
was determined by a spectrophotometer. Approximately 30µg to 70µg of total 
proteins was used for each western blot. The protein bands were separated on 6% 
to 15% resolving SDS-PAGE gel depending on the size of the protein band that 
was being detected at a voltage of 70V to 150V. The transfer of the protein bands 
on the SDS-PAGE gel to the nitrocellulose membrane was usually transferred at 
30V for 15 hours or 100V for 2 hours depending on the size of the protein band 
being analyzed. After the transfer of protein bands onto the nitrocellulose 
membrane, the membrane was blocked with 5% fat-free milk in TBST (50 mM 
Tris.HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) for an hour. After the blocking 
step, the membrane is incubated with the desired diluted primary (1:1000) 
antibody in 5% fat-free milk in TBST for overnight at 4oC. The next day, the 
membrane was washed 3 times, 10 minutes each wash using TBST before it was 
incubated with the diluted secondary (1:1000) antibody conjugated to horseradish 
peroxidase (HRP) for 2 hours at room temperature. The membrane was then 
washed 3 times again, 10 minutes each wash using TBST and after this, the 
various protein bands were analyzed by means using enhanced 
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2.2.20 Cell cycle analysis via BrdU 
The cells were similarly seeded at a concentration of 5 x 105cells in 10ml 
of culture medium in 10-cm tissue culture plate and incubated at 37oC in a 5.0% 
CO2 incubator. After 24 hours, the culture medium was aspirated and the cells 
were rinsed 3 times with serum-free culture medium replaced with 10ml of serum-
free culture medium for 24 hours at 37oC in a 5.0% CO2 incubator to synchronize 
the cell cycle of the cells at G0 resting phase. The next day, 100µl of diluted BrdU 
solution (1mM) were added to the 10-cm tissue culture plate and incubated for an 
hour at 37oC in a 5.0% CO2 incubator. The cells harvested as a cell pellet in 1.5ml 
microcentrifuge tube were resuspended with 100µl of BD Cytofix/Cytoperm 
Buffer and incubated on ice for 30 minutes. The cells were washed once with 1ml 
of 1x BD Perm/Wash Buffer with the supernatant removed and subsequently, the 
cell pellet was resuspended in 100µl of Cytoperm Plus Buffer and incubated on 
ice for 10 minutes. The wash was repeated again with 1ml of 1x BD Perm/Wash 
Buffer and resuspended in 100µl of Cytofix/Cytoperm Buffer for 5 minutes at 
room temperature. There was a final wash with 1ml of 1x BD Perm/Wash Buffer 
before the cells were resuspended in 100µl of diluted DNase incubated at 37oC for 
an hour. This was followed by washing with 1ml of 1x BD Perm/Wash Buffer 
with the supernatant removed followed by resuspending the cells in 50µl of BD 
Perm/Wash containing diluted fluorescent anti-BrdU antibodies for 20 minutes at 
room temperature. The cells were then washed again with 1ml of 1x BD 
Perm/Wash Buffer with the supernatant removed and resuspended in 20µl of the 
7-aminoactinomycin D (7-AAD) solution. 1ml of PBS containing 5mM of EDTA 
was added to each tube and the cells were then analyzed by fluorescence activated 
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cell sorting (FACS) at 20,000 events using quadrant plot analysis plot on a flow 
cytometry (Calibur) (Becton Dickinson, USA). 
 
2.2.21 Flank and NOD-SCID/J Intracranial mouse tumor model 
All animal-related procedures described in this study were approved by our 
IACUC. The NOD-SCID/J mice were allowed to acclimatize for 2 weeks in the 
specific pathogen free (SPF) room before the commencement of the experiment. 
The mouse was anesthetized with 50µl to 60µl of anesthesia (0.5ml ketamine, 
0.5ml xylazine and 2.3ml sterile water) intra-peritoneally and was allowed 5-10 
minutes for the anesthesia to take effect. For the MCF-7 subcutaneous injections, 
6-week-old NOD-SCID mice were similarly allowed to acclimatize for 2 weeks 
before the start of the experiment. Each mouse was anesthetized before being 
injected subcutaneously into the right rear flank with 100µl of phosphate-buffered 
saline (PBS) alone (as a control) or containing 3 x 106 MCF7-vector or MCF7-
parkin stable cells. Tumor formation in injected mice was monitored daily. Where 
visible tumor was formed, its length (L) and width (W) were measured, and the 
tumor volume, i.e. L x W2/2, subsequently calculated. The anesthetized mouse 
was placed on the stage positioned in the centre of the stereotaxic frame with the 
head of the mouse immobilized through the positioning catch on the ears and 
mouth of the mouse anchored on the teeth grip. A fine scissors was used to make 
an incision on the head of the mouse to expose the location of bregma 
(intersection between the sagittal suture and the coronal suture) on the cranium of 
the mouse. The location of the coordinates of implantation was designated at 
+2mm, +1.5mm, -2.5mm with respect from the position of the bregma and the 
position was marked off. The Hamilton syringe was then flushed 5 times with 
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sterile PBS before 2µl of PBS containing 250,000 cells was drawn into the 
Hamilton syringe and the syringe was carefully positioned over the site of 
implantation. A burr drill operated at maximum speed was used to create a hole 
which is just large enough for the needle of the Hamilton syringe to pass through 
taking extreme care not to penetrate into the brain while drilling. Once the hole 
was created, the needle on the Hamilton syringe was lowered 2.5mm into the 
brain somewhere in the middle of the cerebral cortex and the cells were injected 
with the help of an auto-injector at the rate of 0.1µl/minute. After the injection had 
been completed, an additional 5 minutes of waiting time was used before the 
needle was retracted out of the cerebral cortex, this was to try to prevent any 
backflow or leakage of cells from the site of implantation. The head of the mouse 
was sutured up and its breathing, body temperature and color of eye and tail 
monitored for about 5 minutes before it was replaced back into its cage wrapped 
up with a layer of sterile tissue paper over the body to keep it warm. The mice 
were then observed daily for neurological deficits like ataxia and perfusion was 
performed on any first signs and indications of neurological deficits. The brains of 
the mice are then fixed in 4% paraformaldehyde for up to a maximum of 3 days 
before they are embedded in paraffin wax for sectioning purposes. 
 
2.2.22 NOD-SCID/J Intracranial mouse survival assay 
 In order to determine if there are any differences in the survival rates of 
NOD-SCID mice implanted with parkin-expressing or vector-containing U-87MG 
cells, 3 groups of 12 mice were set up and 250,000 cells of each parkin-expressing 
(PK#7 or PK#19) and 1 vector control (Vector#22) cell types were stereotaxically 
implanted respectively in each group according to the method as described in 
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section 2.2.21. An additional PBS group was set up to as a solvent control group 
whereby the mice are just stereotaxically injected with PBS. The mice were 
monitored daily for onset of neurological deficits and ataxia for about 150 days 
and their survival rates were documented. 
 
2.2.23 Microarray 
Total RNA from the various U-87MG parkin expressing and vector control 
cells were extracted using the RNeasy Mini Kit (Qiagen, USA). The concentration 
and quality of the total RNA extracted was assessed by the NanoDrop ND-1000 
machine (Thermo Scientific, USA) and the Bioanalyzer (Agilent, USA). After the 
quality of the RNA was ascertained, the GeneChip® WT cDNA Synthesis and 
Amplification Kit (Affymetrix, USA) was used to generate the first and second 
cycle cDNA synthesis and the cRNA synthesis through in vitro transcription 
amplification. After the second cycle cDNA synthesis and cRNA hydrolysis step, 
the GeneChip® WT Terminal Labeling Kit was used for the fragmentation and 
terminal labeling of the cDNA to generate targets compatible with the GeneChip 
arrays. After which, the targets were hybridized to the GeneChip® Human Gene 
1.0 ST Array which constituted 28,000 gene-level probe sets. 
  300ng of total RNA were used for the experiments and the arrays were 
washed and stained using the FS450_0007 fluidics protocol and scanned using an 
Affymetrix 3000 7G scanner. The scanned images were inspected for 
hybridization efficiency and CEL files generated from GCOS (GeneChip 
Operating Software) were imported into Expression Console (EC) 1.1 software for 
array QC. The CEL data files were analyzed on Biotique XRAY using mixed 
ANOVA model with quantile normalization employed. The multiple test 
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correction was done using Benjamini-Hochberg false discovery rate of less than 
0.005 and the display of results with fixed factor absolute fold change greater than 
1.5 folds.  
 
2.2.24 Bioinformatic analysis of microarray data 
Bioinformatic analysis of the microarray data obtained in our study was 
performed with the help from Miss Felicia Ng, a bioinformatician at the Singapore 
Institute of Clinical Studies. CEL files from the Affymetrix Human Gene 1.0 ST 
Arrays were processed using the R statistical software and Bioconductor packages 
(R Dev Core Team, 2010; Gentleman et al., 2004).  The xps package (Stratowa, 
2010) was used to perform RMA normalization and filter probes with non-
significant Detection Above Background (DABG) p-values (threshold set at 0.01).  
After that, an ‘Expression Set’ was created using the Biobase package (Gentleman 
et al., 2004) for further analysis in R.  Raw and processed data are available on the 
GEO public database website (GSE29494) [Link: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=dxstlywiiykyqvk&acc=GS
E29494].  Differentially expressed genes between parkin samples (PK7, PK19, 
PK25) and vector samples (V8, V17, V22) were generated using the samr package 
with false discovery rate less than 0.001.  Analysis of pathways and gene sets 
implicated by Parkin expression was carried out using MetaCore from GeneGo 
Inc. and Gene Set Enrichment Analysis (Subramaniam et al., 2005).  To generate 
the Parkin signature, probes with log fold change 1.2 were selected and applied to 
downstream analysis.  In order to quantify the extent of Parkin pathway activation, 
we adapted the Connectivity Map approach (Lamb et al, 2006).  Briefly, the 
Connectivity Map is a pattern matching approach, based on the Kolmogorov 
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Smirnov statistic, to determine the concordance of the gene signature to gene 
expression levels in the clinical sample.  Public GBM datasets with clinical data, 
in terms of survival length, were obtained from either the GEO database or the 
database website.  The following datasets were used in the analysis: Rembrandt 
(http://caintegrator-info.nci.nih.gov/rembrandt) and Freije (GSE4412)(20).  In the 
case of Rembrandt dataset, only survival ranges were available on the website.  
Hence, the lower limit of the range was used in this analysis.  To generate the 
reference profiles, the datasets were processed using the mas5 algorithm, quantile 
normalized and median-centered.  Expression values less than the threshold value 
of 50 were replaced with the threshold value.  The Parkin gene signature was 
compared to each sample in the 2 reference profiles mentioned above and an 
activation score was calculated using the Connectivity Map approach to identify 2 
groups of patients:  Parkin (+) and Parkin (-) (18, 19).  The calculation of the 
activation score and p-value are as described in Lamb et. al, 2006.  In this study, a 
positive activation score (the Parkin(+) group) indicate that the sample is 
positively associated to the gene signature and vice versa.  Kaplan Meier and Cox 
regression analysis of Parkin(+) and Parkin(-) group were done in R using the 
survival package. 
 




PARKIN MITIGATES THE RATE OF GLIOMA CELL 
PROLIFERATION IN IN VITRO AND IN VIVO  
 
3.1 Overview 
 As mentioned in the introduction, much of the interest in characterizing the 
function of the parkin gene has been directed towards understanding its role in 
neurodegeneration by virtue of its original association with PD (Kitada et al., 
1998). However, aberrant parkin function has also been linked to several other 
disorders including cancer (Cesari et al., 2003). Comparatively, the role of parkin 
in these disorders is less well characterized. In particular, despite a consistent 
association between parkin expression alterations and cancers, there was a paucity 
of reports (at the time when I first started the project) that demonstrates robustly 
the functional consequence of parkin expression restoration in parkin-deficient 
cancer cells. As a proof of concept that parkin can mitigate cancer growth, I have 
together with my colleague (i.e. Tay Shiam-Peng) examined the tumor-
suppressing effects of restoring parkin in breast cancer cells, which have been 
reported to be otherwise highly deficient in parkin expression (Cesari et al., 2003). 
Using a battery of in vitro cancer cell assays and an in vivo NOD-SCID mouse 
model of tumor formation, we found that parkin over-expression in breast cancer 
cells can indeed slow down their rate of proliferation both in vitro and in vivo 
(Tay et al., 2010). With the support from this proof of concept study that parkin is 
capable of exerting tumor suppression, I went on to characterize the role of parkin 
in gliomagenesis and subsequently demonstrated that parkin expression is 
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similarly deficient in glioma cell lines and that its expression restoration mitigates 
cancer growth in glioma cells, the results of which are presented below.  
 
 3.2  Results 
 
3.2.1  Ectopic parkin expression in parkin-deficient MCF-7 breast cancer 
cells mitigates their proliferation in vitro and in vivo.  
 Consistent with the finding by Cesari and colleagues (Cesari et al., 2003), 
our lab has demonstrated that parkin expression is significantly downregulated at 
both the transcript and protein levels in a variety of breast cancer cell lines, 
including MCF-7, as well as in primary human breast cancer samples (Tay et al., 
2010). To examine the functional effects of restoring parkin expression in parkin-
deficient breast cancer cells, we generated stable clones of MCF-7 cells 
expressing FLAG-tagged parkin (MCF-7-PK) or containing vector alone as a 
control (MCF-7-Vector). Three individual parkin-positive MCF-7 clones (#5, 7 
and 11) were selected for our experiments to minimize clonal variation. Notably, 
all of these parkin-positive clones express parkin at a higher level than vector 
control or parental cells (Fig. 3.1A), but are otherwise similar morphologically. A 
simple population growth assay reveals that the proliferation rate of parkin-
expressing MCF-7 cells is significantly reduced compared to control cells (Fig. 
3.1B), suggesting that ectopic parkin expression in MCF-7 cells mitigates their 
growth. Since cancer cells are anchorage-independent and have the ability to form 
colonies in soft agar, we also examined whether ectopic parkin expression in 
MCF-7 cells compromise its ability to generate colonies in soft agar. We found 
that the number of soft agar colonies formed by parkin-expressing MCF-7 cells is 
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dramatically reduced and the size of these colonies also tends to be smaller 
compared to those generated by control MCF-7 cells (Fig. 3.1C).  
 
Figure 3.1 Over expression of parkin in MCF-7 cells mitigates their proliferation 
rate (A) Anti-FLAG and anti-parkin immunoblots of total lysates prepared from native 
MCF-7 cells (-), vector control (V) and the parkin-expressing stable clones (#5, 7 & 11). 
Equal loading of the different lysates was verified by anti-actin immunoblotting. (B) 
Graphical depiction of the percentage of cells undergoing cell proliferation, as measured 
by cell population number, in MCF-7 vector control and parkin-expressing stable cell 
lines. (C) Representative images showing apparent decreased ability of parkin-expressing 
MCF-7 cells in forming colonies in soft agar compared to MCF-7-vector control. These 
experiments were performed at least three times. (*P < 0.05, Student’s t-test). 
 
To extend our above findings, I examined the effects of parkin over 
expression on the ability of MCF-7 cells to generate solid tumor in vivo. A flank 
tumor model (n = 9 for each group), where NOD-SCID mice were injected 
subcutaneously with parkin expressing or control MCF-7 cells, or otherwise with 
PBS alone, was used for this purpose. Over a period of four weeks post-injection, 
I observed visible tumor formation that progressively increases in size in mice 
injected with control or parkin-expressing MCF-7 cells, but not in those injected 
with vehicle alone (Fig. 3.2A, not shown for PBS control). Consistent with our in 
vitro findings above, I found that parkin-positive clones tend to generate tumors of 
significantly smaller volume and mass in vivo compared to control cells (Fig. 
3.2A-C). Taken together, our results demonstrate that ectopic parkin expression in 
parkin-deficient MCF-7 cells mitigate its proliferation both in vitro and in vivo, 
and strongly suggest a negative role for parkin in breast cancer cell proliferation. 





Figure 3.2 Parkin expression mitigates MCF-7 cancer cell growth in vivo. (A) Graph 
showing the volume (left and middle panels) and mass (right panel) of tumor generated 
by different cell types in NOD-SCID mice (n = 9) at day 14 and day 28. The experiment 
was duplicated with essentially the same result (*P < 0.05, **P < 0.001, Student’s t-test). 
(B) Images showing the presence of macroscopic tumor in NOD-SCID mice at 21 days 
post-injection with MCF-7 vector control cells, in contrast to those injected with MCF-7 
cells stably expressing parkin. (C) Images showing tumors resected from mice injected 
with MCF-7 vector control cells (top panels) or parkin-expressing MCF-7 cells (bottom 
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3.2.2 Parkin expression is downregulated in various glioma cell lines 
A recent genomic profiling study revealed discrete deletion on 
chromosome 6 involving the parkin gene in glioblastoma multiforme (Mulholland 
et al., 2006), the most malignant form of astrocytic gliomas. In addition, recent 
comprehensive genomic characterization of 206 glioblastomas revealed 
significantly recurrent focal alterations like homozygous deletions in the regions 
of parkin gene (McLendon et al., 2008). To examine if parkin expression is 
affected in glioma cells, I conducted a preliminary study on the abundance of 
parkin transcripts in several glioma cell lines using a semi-quantitative RT-PCR 
assay, and found apparent reduction in the level of parkin mRNA in all the glioma 
cell lines examined, including U-87MG, U-373, U-251 and T-98G compared to 
control HEK cells (Fig. 3.3A). Consistent with this, subsequent quantitative 
analysis of parkin mRNA expression using Real-time PCR reveals an average of 
16-fold decrease in the levels of parkin transcripts in these glioma cell lines 
compared to control HEK cells (Fig. 3.3B). The dramatic reduction in parkin 
expression levels correlate well with the amount of parkin protein in extracts 
derived from the various glioma cell lines examined (Fig. 3.3C). Collectively, 
these results demonstrated that parkin expression is significantly down-regulated 
in glioma cells and suggest that aberrant parkin expression may be relevant to 
gliomagenesis. 
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Figure 3.3 Parkin expression is down-regulated in various glioma cell lines. (A) 
Semi-quantitative RT-PCR results showing the relative expression levels of parkin 
transcripts in HEK, MCF-7 and several glioma cell lines. (B) Bar-graph depicting the 
real-time quantification of parkin mRNA levels in various glioma cell lines. The non 
tumor-derived HEK 293 and the tumor-derived MCF-7 cells were used as controls. (C) 
Representative anti-parkin immunoblot showing the relative expression of endogenous 
parkin protein in various glioma cell lines. The blot was stripped and reprobed with anti-
actin to reflect loading variations. These experiments were performed at least three times. 
(*P < 0.05, **P < 0.001, Student’s t-test).  
 
3.2.3 Parkin is uniformly localized in the cytoplasm of various glioma cell 
lines 
 Besides expression downregulation, I wished to determine if there is any 
aberrant localization of parkin in the various glioma cell lines. Several groups 
including ours have previously demonstrated that mutation or stress-induced 
parkin solubility alteration and mislocalization in the cell can impair its function 
(Reviewed in Tan et al., 2009). However, no aberrant localization of parkin was 
observed. Indeed, immunocytochemical analysis reveals a largely uniform 
cytoplasmic distribution of parkin which is consistent throughout the various 
glioma cell lines examined (Fig. 3.4A-D). Although at times punctate, there is no 
obvious evidence of parkin aggregates in these cells (Fig. 3.4). 
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Figure 3.4 Parkin is uniformly localized in the cytoplasm in various glioma cell lines. 
Representative confocal images showing anti-parkin (red) staining and DAPI (anti-nuclei, 
blue) staining in various glioma cell lines (A) U-87MG (B) U-373 (C) U-251 (D) T-98G. 
Scale bar at 10μm on the lower left of each panel. 
 
3.2.4 Ectopically-expressed parkin mitigates the rate of proliferation of 
parkin-deficient U-87MG glioma cells in vitro 
In order to investigate the effects of parkin on glioma, stable clones of U-
87MG stably expressing vector alone as a control (U-87MG-Vector) or containing 
FLAG-tagged parkin (U-87MG-PK) in a mammalian expression vector, pcDNA3 
were generated (Fig. 3.5A).  The glioma cell line, U-87MG cells was used for this 
purpose because it expresses parkin very poorly and is also a popular cell model 
for glioma studies. As in the case with MCF-7-parkin stable cells, three parkin-
expressing U-87MG clones were chosen to minimize clonal variations. All the 
parkin-positive clones express parkin at a significantly higher level than vector 
control or parental cells (Fig. 3.5A), but are otherwise similar morphologically. 
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 The respective rate of proliferation in the vector or parkin-expressing U-
87MG cells were analyzed by means of a variety of proliferation assays. A simple 
cell count assay (via haemocytometer) revealed that the rate of proliferation in 
parkin-expressing U-87MG cells is significantly reduced compared to control 
cells (Fig. 3.5B), suggesting that ectopic parkin expression in U-87MG cells 
mitigate their growth. Consistent with this, there is also reduced incorporation of 
BrdU, a thymidine analogue, in parkin-expressing U-87MG cells compared to U-
87MG vector control cells (Fig. 3.5C). Moreover, ectopic parkin expression in U-
87MG cells compromise their ability to generate colonies in soft agar. It is also 
noteworthy that the size of the colonies formed by parkin-expressing U-87MG 
cells in soft agar is also comparatively smaller than those generated by U-87MG 
vector control cells (Fig. 3.5D). Taken together, my results above based on a wide 
spectrum of in vitro cancer cell assay strongly suggest that restoration of parkin 
levels in parkin-deficient glioma cells could exert an anti-proliferative effect on 
their growth. 
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Figure 3.5 Over expression of parkin in U-87MG glioma cells mitigates their 
proliferation rates. (A) Anti-FLAG and anti-parkin immunoblots of total lysates 
prepared from U-87MG vector control (V) and parkin-expressing stable clones (#7, 19 & 
25). Equal loading of the different lysates was verified by anti-actin immunoblotting (B-
C) Bar-graph showing the percentage of cells undergoing cell proliferation in U-87MG 
vector control and parkin-expressing stable cell lines, as measured by (B) cell population, 
or (C) the BrdU assay. This experiment is repeated at least three times. (*P < 0.05, **P < 
0.001, Student’s t-test) (D) Representative images showing apparent decrease ability of 
parkin-expressing U-87MG cells in forming colonies on soft agar compared to U-87MG-
vector control. 
 
3.2.5 T415N mutant parkin expression in U-87MG glioma does not affect 
rate of cellular proliferation 
 In order to determine if the reduced rate of cellular proliferation observed 
above was attributed to parkin’s catalytic activity, I created T415N mutant parkin 
stables and vector control (Fig. 3.6A & B) in U-87MG cell line and assessed their 
rate of cellular proliferation using the simple cell count assay. The T415N 
mutation is found on the C-terminal of parkin protein located in between IBR and 
RING2 domain has been demonstrated to be a “ligase-dead” or “catalytically null” 
parkin mutant (Fig. 3.6A) (Matsuda et al., 2006). There is no observable 
difference between the rate of cellular proliferation of T415N mutant parkin 
expressing U-87MG cells as compared to the vector control (Fig. 3.6C), 
suggesting that the catalytic activity of parkin is important for its tumor 
suppression property.  
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Figure 3.6 Over expression of T415N mutant parkin in U-87MG glioma cells do 
not affect their rate of cellular proliferation as compared to the vector control. 
(A) Schematic representation of parkin protein illustrating the positions of the various 
point mutations of parkin (B) Anti-FLAG and anti-parkin immunoblots of total lysates 
prepared from U-87MG vector control (V) and T415N mutant parkin-expressing stable 
clones (#5, 7 & 8). Equal loading of the different lysates was verified by anti-actin 
immunoblotting (C) Line-graph showing the percentage of cells undergoing cell 
proliferation in U-87MG vector control and T415N mutant parkin-expressing stable cell 
lines. This experiment is repeated at least three times. 
 
3.2.6 Parkin expression in U-87MG cells reduces their ability to generate 
tumor in vivo 
 Although I have shown that functional parkin is capable of suppressing 
glioma growth in vitro, there is a need to ascertain its ability to do so in vivo. 
Accordingly, I examined the effects of parkin over-expression on the ability of U-
87MG cells to generate solid tumor in vivo. An intracranial glioma model (n = 5 
for each group), which involved the injection of parkin-expressing or control U-
87MG cells into the cerebral cortex of NOD-SCID mice, was used for this 
purpose. I have elected to use this model as unlike flank tumor model, the 
intracranial model better recapitulates the features of brain cancer. At four weeks 
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post-injection, I observed the appearance of macroscopic tumors in four out of 
five dissected brains of mice injected with vector control U-87MG cells, but none 
in those injected with parkin-expressing U-87MG cells (Fig. 3.7A) or vehicle 
alone (not shown). The formation of the macroscopic tumors was the end result of 
the growth of the tumor cells along the injection tract created when implanting the 
tumor cells. Consistent with this, the average weight of brains harvested from all 
five mice injected with parkin-expressing U-87MG cells is significantly reduced 
compared to those harvested from control mice (Fig. 3.7C).  Further, histological 
examination of brain sections derived from these mice revealed that NOD-SCID 
mice injected with U-87MG vector control cells via the intra-cranial route 
developed visibly larger tumor in the brain at the end of the experimental period 
compared to those injected with U-87MG cells stably expressing parkin (Fig. 
3.7B).  Taken together, my results strongly support a negative role for parkin in 
glioma cell proliferation. 
 
 
Figure 3.7 Parkin expression in U-87MG cells reduces their ability to generate 
tumor in vivo. (A, top) Digital images showing macroscopic glial tumors (arrows) that 
developed in the brains of NOD-SCID mice 4 weeks after being injected with U-87MG 
vector control cells via the intra-cranial route. (A, bottom) In contrast, mice injected with 
U-87MG cells stably expressing parkin show no obvious signs of macroscopic tumors.  
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(B) H&E stained sections showing that NOD-SCID mice injected with U-87MG vector 
control cells (left) via the intra-cranial route that do not exhibit macroscopic tumors 
developed visibly larger tumor in the brain after 4 weeks, compared to those injected with 
U-87MG cells stably expressing parkin, as indicated (right). (C) Masses of brains 
between NOD-SCID mice 4 weeks after being injected with U-87MG vector control cells 
and U-87MG cells stably expressing parkin. Images shown above are of the same 
magnification. 
 
3.2.7 Parkin expression in U-87MG cells exhibit significantly improved 
survival of NOD-SCID mice as compared to U-87MG vector control 
As an extension of the in vivo study, I repeated the above experiment but 
allowed injected mice from different groups (i.e. U-87MG-vector, U-87MG-
parkin #7 and #19; n = 10 for each group) to live beyond four weeks to examine 
their respective survival profile. I found that whereas NOD-SCID mice harbouring 
glioma generated from U-87MG-vector control cells readily succumb to the 
tumor, those injected with U-87MG-parkin #7 exhibit significantly better survival 
(Fig. 3.8A). Curiously, the U-87MG-parkin #19 group showed a mortality curve 
that is between vector and U-87MG-parkin #7 groups, but with a profile tending 
towards and not significantly different from the vector group (Fig. 3.8A). At post-
mortem analysis, I found that tumor derived from U-87MG-parkin #19 had lost 
much of its parkin expression over time, which likely accounted for its survival 
profile, whereas those derived from U-87MG-parkin #7 exhibit robust parkin 
expression even after prolonged periods in vivo (Fig. 3.8B). Thus, parkin 
expression appears to correlate inversely with cancer mortality. 
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Figure 3.8 Parkin expression correlates inversely with cancer mortality in a 
mouse model of glioma. (A) Kaplan-Meier curves depicting the mortality of mice 
injected with U-87MG cells stably expressing vector (V22) or parkin (PK7 and PK19), as 
indicated. Mice injected with vehicle alone (PBS) act as control for the experiment. (B) 
Anti-parkin immunoblot of brain lysates prepared from 2 representative animals from 
each group. The blot was stripped and reprobed with anti-actin to reflect loading 
variations. “Ipsilateral” refers to tumor-harboring side of the brain while “Contralateral” 
refers to the non-injected side. Note that parkin expression is dramatically diminished in 
lysates derived from the ipsilateral brains of mice injected with U-87MG-parkin #19 




The main finding of my results chapter here is that functional parkin 
expression in otherwise parkin-deficient breast cancer and glioma cells exerts 
significant negative effects on their respective rate of proliferation. At the same 
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time, I also found that parkin expression may reduce glioma-associated mortality, 
at least in animal models. Taken together, my results are therefore consistent with 
the original suggestion by Cesari et al that parkin may act as a tumor suppressor. 
Despite a consistent association between parkin expression alterations and 
cancers, the pace of research surrounding the role of parkin in cancer continues to 
lag far behind investigations that seek to understand its role in neurodegeneration 
(Veeriah et al., 2010). Indeed, only a few groups thus far have reported the 
functional consequence of parkin expression restoration in cancer cells. By means of a 
wide spectrum of proliferation assays that include population growth, anti-BrdU-
staining, soft-agar colony formation as well as generation of solid tumors in NOD-
SCID mice, I show here that parkin is a potent tumor suppressor. Perhaps to 
overcome this effect by parkin, cancer cells apparently devised ways to down-
regulate parkin expression. Indeed, several groups have documented parkin gene 
alterations and concomitant reduction in parkin transcript abundance in a wide 
variety of cancers that includes breast, liver, non-small-cell lung and ovarian 
carcinoma (Cesari et al., 2003, Denison et al., 2003, Picchio et al., 2004, Wang et 
al., 2004). Here, I have added glioma cells to the list of parkin-deficient cancer 
cells. Notably, the localization of parkin in these cells is otherwise not grossly 
affected. 
Although an apparent E3-independent activity of parkin that is relevant to 
cancer has been reported by da Costa et al (da Costa et al 2009), I found here that 
parkin catalytic activity is essential for its ability to suppress glioma cell 
proliferation. The RING2 catalytic missense mutant, T415N, completely abolishes 
the tumor suppressive effects of parkin on glioma cells. Interestingly, T415N is a 
disease-associated parkin mutant isolated from PD patients that has been 
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demonstrated to be devoid of catalytic activity (Matsuda et al., 2006, Chew et al., 
2011). Supporting this finding, Veeriah and colleagues have identified for the first 
time several inactivating somatic parkin mutations in GBMs. Like PD-associated 
parkin mutations, the majority of cancer-associated parkin mutations are found on 
the RING catalytic box of the protein (Veeriah et al., 2010). Collectively, these 
results suggest that the expression level of parkin and its catalytic competency are 
both needed to keep the cell cycle in balance.  
In view of reports suggesting that parkin may regulate the cell cycle by 
means of its ability to control the level of cyclin E, I next sought to determine if 
parkin can influence the cell cycle program of glioma cells, and if so, whether it 
involves cyclin E. Aspects on how parkin can potentially regulate glioma cell 
cycle will be discussed in the next chapter. Because my above results also reveal a 
potential relationship between parkin expression and survival of the outcome of 
glioma-bearing animals, I was interested to see if this relationship holds true for 
human glioma patients, which will be discussed in chapter 5. 




PARKIN MITIGATES CELL CYCLE PROGRESSION THROUGH 
REGULATION OF CELL CYCLE REGULATORY MACHINERY AND 
PI3K/AKT CELLULAR SURVIVAL PATHWAY 
 
4.1 Overview 
 I have demonstrated in the previous chapter that parkin is capable of 
mitigating the rate of cellular proliferation of U-87MG glioma cells both in vitro 
(using the simple cell count, BrdU incorporation assay, soft-agar colony assay) as 
well as in vivo (using the non-obese diabetic-severe combined immunodeficiency 
[NOD-SCID] intra-cranial mouse model). The next step would be to determine i) 
at which stage of the cell cycle does parkin affects, ii) the cell cycle regulatory 
proteins that are involved and iii) the mechanism which is responsible for the 
reduced rate of proliferation in parkin-expressing relative to control U-87MG 
cells.  
As mentioned in the introductory chapter, the cell cycle comprises of 4 
stages namely the G1-phase, S-phase and G2/M-phase and progression through 
these phases are regulated by orderly sequential expression, activation and 
inhibition of cyclin-dependent kinase (CDK), cyclins and CDK inhibitors (CDKI). 
In the G1-phase following mitogenic stimulation, cyclin D are synthesized and 
they bind to CDK4 and CDK6 for activation, which allow for progression of cell 
cycle through the G1-phase. Towards the end of the G1-phase, cyclin E is induced 
and it binds with CDK2 to form a cyclin E/CDK2 complex which is essential for 
transition from G1-phase into S-phase. DNA synthesis during S-phase is 
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facilitated by an active cyclin A/CDK2 complex. After the DNA synthesis is 
completed, cyclin A would form a complex with CDK1 to enable the progression 
of cell cycle through the G2-phase. At the G2/M-phase transition, cyclin A would 
be degraded and cyclin B would be associated with CDK1 to form a complex 
which is required for progression through the mitosis stage. Notably, the 
expression of parkin was previously shown to attenuate the accumulation of cyclin 
E (Staropoli et al., 2003), which provides a mechanism by which parkin can 
promote cell cycle arrest at the G1-phase. It is also noteworthy that in gliomas, 
there is hyperactivation of the PI3K/Akt pathway frequently caused by PTEN 
mutations and also amplification of growth-promoting signaling cascades, for 
example through activating mutations in EGF receptors. A combination of 
dysregulated cell cycle and enhanced mitogenic signaling probably account for 
gliomagenesis. 
Here, I demonstrated that parkin-mediated suppression of glioma growth is 
related to its ability to promote cell cycle arrest at the G1 phase. Surprisingly, the 
level of cyclin D1, but not cyclin E, is reduced in parkin-expressing glioma cells. 
Further, parkin expression also leads to a selective downregulation of Akt serine-
473 phosphorylation. Supporting this, cells derived from parkin null mouse 
exhibit increased levels of cyclin D1 and Akt phosphorylation and divide 
significantly faster compared to their wild type counterparts, all of which are 
suppressed following the re-introduction of parkin into these cells. Taken together, 
my results have therefore shed light onto the mechanism underlying parkin-
mediated suppression of glioma growth. 
  
 




4.2.1 Parkin expression in U-87MG cells mitigates cell cycle progression in 
asynchronized U-87MG cell line 
As an initial approach to examine whether parkin expression affects the 
cell cycle profile of U-87MG cells, asynchronous parkin-expressing U-87MG 
cells together with their respective vector control were analyzed for their 
distribution in various stages of the cell cycle using propidium iodide. Consistent 
with their slower growth rate, the percentage of parkin-expressing U-87MG cells 
at the G1-phase is significantly higher than vector control cells. Reciprocating this 
phenomenon is a corresponding reduction in the number of parkin-expressing U-
87MG cells entering the S-phase and subsequently the G2/M-phase as compared 
to vector control cells (Fig. 4.1). 
 
 
Figure 4.1 Parkin expression in U-87MG cells mitigates cell cycle progression in 
asynchronized U-87MG cell line. Percentage of asynchronous parkin expressing and 
vector control cells in the various stages of cell cycle progression, G1-phase, S-phase and 
G2/M-phase as measured by propidium iodide uptake via flow-cytometry. This 
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4.2.2 Parkin expression in U-87MG cells mitigates cell cycle progression in 
synchronized U-87MG cell line  
A similar phenomenon as above was observed in cell cycle synchronous 
parkin-expressing U-87MG cells, which exhibit reduced tendency to enter both 
the S-phase and the G2/M-phase as compared to the vector control (Fig. 4.2A). 
This phenomenon is clearly related to the catalytic viability of parkin as mutant 
parkin (T415N)-expressing U-87MG stable cells fail to delay the entry of cells 
into the mitotic phase (Fig. 4.2B). Instead, these mutant parkin-expressing cells 
exhibit a tendency to be distributed in the S-phase and G2/M-phase as compared 
to their vector control counterparts (Fig. 4.2B).  
 
Figure 4.2. Parkin overexpression in U-87MG cells delays entry of synchronized U-
87MG cells into mitotic phase.  Bar graph showing the percentage of U-87MG-vector 
and U-87MG-wild type parkin-expressing cells (left) or U-87MG-vector and U-87MG-
mutant parkin T415N cells (TN5, 7 & 8) (right) at different stages of the cell cycle as 
measured by flow cytometry. n=3 (*P < 0.05, Student’s t-test). 
 
4.2.3 Parkin expression in U-87MG cells reduces cyclin D1 but not cyclin E 
levels 
I next examined if enhanced cyclin E proteolysis may account for the cell 
cycle profile in U-87MG-Parkin cells. Surprisingly, I did not detect an apparent 
difference in the steady state level of cyclin E between parkin-expressing and 
control U-87MG cells (Fig. 4.3A). Instead, I found that the expression of cyclin 
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D1 (which, like cyclin E, is also involved in G1 to S transition), is dramatically 
repressed in parkin-expressing U-87MG cells (Fig. 4.3A). In contrast, cyclin D1 
levels remain largely unaltered in U-87MG cells stably expressing the T415N 
mutant (Fig. 4.3B), which emphasizes the need for parkin to be functional for it to 
influence the progression of cell cycle. The presence of a doublet in the cyclin D1 
immunoblot is due to the presence of phosphorylated forms of cyclin D1. 
 
 
Figure 4.3. Parkin overexpression in U-87MG cells reduces the level of cyclin D1. (A) 
Immunoblots showing the levels of cyclin E and cyclin D1 in lysates prepared from 
native U-87MG cells (U-87MG), U-87-vector (Vector) and FLAG-parkin-expressing 
stable clones (PK7, 19 & 25). (B) As in (A) except parkin-expressing cells were replaced 
by mutant parkin-expressing (T415N) clones. The anti-cyclin D1 immunblots from three 
independent experiments were used to derive the relative densitometric units of cyclin D1 
(normalized to respective actin level), which is presented as a histogram on the right.  
Equal loading of the different lysates was verified by anti-actin immunoblotting. All 
experiments were performed in triplicates. 
 
Together, these results suggest that cyclin D1 expression, rather than cyclin E, 
possibly underlies parkin’s ability to influence the cell cycle program of glioma 
cells. 
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4.2.4 Akt phosphorylation is elevated in glioma cells  
 As mentioned, over-activation of the PI3 kinase/Akt signaling pathway is a 
frequent feature of glioma cells. Consistent with this, PTEN-deficient U-87MG, 
U-373MG and U-251MG cells exhibit elevated levels of phosphorylated Akt 
compared to T-98G, a PTEN-expressing glioma cell line  (Fig. 4.4).  
 
Figure 4.4. Phospho-Akt expression in various 
glioma cell lines. Immunoblots showing the levels 
of phoshorylated-Akt (S473) and total Akt in lysates 
prepared from various commercial cell lines. Three 
out of four glioma cell lines examined (U-87MG, 
U373MG & U251MG) exhibit enhanced phospho-
Akt level. 
 
4.2.5 Akt Ser-473 phosphorylation is significantly reduced in parkin-
expressing glioma cells. 
Notably, the complete activation of Akt requires phosphorylation at two 
amino acids positions namely serine-473 (Ser 473) and threonine-308 (Thr 308). 
To investigate whether exogenous parkin expression in U-87MG cells exerts any 
effect on Akt signaling, I immunoblotted lysates prepared from U-87MG parkin 
and U-87MG vector cells with phosphorylation-specific Akt antibodies and found 
that the levels of Akt phosphorylated at Ser-473 is significantly reduced in parkin-
expressing U-87MG cells compared to control cells (Fig. 4.5). This phenomenon 
is not due to changes in Akt expression in the presence of parkin (Fig. 4.5), and is 
not observed when the experiment was repeated with U-87MG cells stably 
expressing parkin T415N mutant (Fig. 4.5), suggesting again that the catalytic 
activity of parkin is important and is required for its effect on Akt Ser-473 
phosphorylation.  
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Figure 4.5. Phosphorylation of Akt at Ser-473 is significantly repressed in parkin-
expressing U-87MG cells. Immunoblots showing the levels of phoshorylated-Akt (S473) 
and total Akt in lysates prepared from U-87MG-vector (Vector) and FLAG-parkin (PK7, 
19 & 25) or FLAG-parkin T415N (TN5, 7 & 9)-expressing stable clones. The anti-Akt 
immunblots from three independent experiments were used to derive the relative 
densitometric units of phospho-Akt (normalized to respective total Akt level), which is 
presented as a histogram (right). 
 
In contrast, phosphorylation of Akt in U-87MG cells at another site, Thr-
308, appears to be unaffected by parkin overexpression (Fig. 4.6A). Consistent 
with this, the levels of activated phosphoinositide-dependent kinase (PDK) 1, an 
upstream effector of Akt Thr-308 phosphorylation, is not appreciably altered in 
parkin-expressing U-87MG cells (Fig. 4.6B). 
 
 
Figure 4.6. Phosphorylation of Akt at Thr-308 is unaffected in parkin-expressing U-
87MG cells. (A) Immunoblots showing the levels of phoshorylated-Akt (T308) and total 
Akt in lysates prepared from U-87MG-vector (Vector) and FLAG-parkin (PK7, 19 & 25) 
expressing stable clones. The anti-Akt immunblots from three independent experiments 
were used to derive the relative densitometric units of phospho-Akt (normalized to 
respective total Akt level), which is presented as a histogram (right). (B) As in (A) 
except anti-phospho-PDK1 and anti-PDK1 were used to probe the immunoblots. 
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4.2.6 Parkin downregulates levels of phosphorylated-Akt (Ser 473) under 
epidermal growth factor (EGF)-stimulation 
In gliomas, there is frequent amplification of EGF receptors, which leads 
to hyperactivation of its tyrosine kinase activity within the cell and thereby 
enhanced oncogenic signaling. As EGF signalling is known to promote Akt 
phosphorylation, I was interested to examine whether parkin suppression of Akt 
Ser-473 persists in the presence of EGF. I therefore looked at the extent of Akt 
Ser-473 phosphorylation in the presence or absence of EGF stimulation. Under 
serum-starved condition, the basal level of Ser-473 phosphorylated Akt in parkin-
expressing U-87MG cells is expectedly reduced compared to control cells (Fig. 
4.7). Upon EGF stimulation, a marked increase in Akt phosphorylation is 
observed in both control and parkin-expressing U-87MG cells, although the 
steady-state levels of Ser-473 phosphorylated Akt in U-87MG-Parkin cells 




Figure 4.7 Parkin downregulates levels of phosphorylated-Akt (Ser 473) even under 
epidermal growth factor (EGF)-stimulated condition in U-87MG cell line (A) Anti-
phosphorylated Akt (Ser 473) and anti-Akt immunoblots of total lysates prepared from U-
87MG vector control (vector) and parkin-expressing stable clones (PK7, PK19 & PK25) 
under non EGF-stimulated and EGF-stimulated (30ng/ml, 2mins) conditions. (B) Bar-
graph depicting densitometric readings of normalized levels of phosphorylated Akt (Ser 
473) against unphosphorylated-Akt in various U-87MG vector control (Vector) and 
parkin-expressing stable cell lines (PK7, PK19 & PK25) These experiments were 
performed at three times. (*P < 0.05, Student’s t-test).  
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Collectively, these results show that parkin-mediated effects on Akt 
phosphorylation works both in the absence or presence of growth factor 
stimulation. At the same time, the results also suggest that parkin-mediated 
suppression of glioma cell growth is in part contributed by its ability to regulate 
growth factor-dependent or independent PI3 kinase/Akt signaling pathway via the 
downregulation of Akt Ser-473 phosphorylation.   
 
4.2.7 Parkin catalytic mutant T415N does not affect the levels of 
phosphorylated-Akt (Ser 473) under epidermal growth factor (EGF)-
stimulated condition in U-87MG cell line 
In order to determine if the catalytic activity of parkin is responsible for 
the downregulation of phosphorylated Akt upon EGF stimulation, mutant parkin 
(T415N) expressing U-87MG were assessed for their levels of phosphorylated Akt 
before and after EGF stimulation. As shown in figure 4.6, the levels of 
phosphorylated Akt at Ser 473 position were relatively unaffected between parkin 
expressing U-87MG cells as compared to the vector controls and they were at 
comparable levels before and after EGF stimulation. 
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Figure 4.8 Parkin mutant T415N does not affect the levels of phosphorylated-Akt 
(Ser 473) under EGF-stimulated condition in U-87MG cell line (A) Anti-
phosphorylated Akt (Ser 473) and anti-Akt immunoblots of total lysates prepared from U-
87MG vector control (vector) and parkin-expressing stable clones (PK7, PK19 & PK25) 
under non EGF-stimulated and EGF-stimulated (30ng/ml, 2mins) conditions. (B) Bar-
graph depicting densitometric readings of normalized levels of phosphorylated Akt (Ser 
473) against unphosphorylated-Akt in various U-87MG vector control (Vector) and 
parkin-expressing stable cell lines (PK7, PK19 & PK25) These experiments were 
performed at three times. (*P < 0.05, Student’s t-test). 
 
 
4.2.8 Parkin null fibroblasts exhibit enhanced proliferation rate that is 
mitigated by parkin expression restoration 
To further support the role of parkin as a suppressor of cellular 
proliferation, I analyzed the growth characteristics of mouse embryonic fibroblasts 
(MEFs) prepared from wild type and parkin null mice that were reported 
previously (Von Coelln et al., 2004). As expected, parkin null fibroblasts exhibit 
significantly enhanced rate of growth over time (Fig. 4.9A). Further, consistent 
with my results presented in Chapter 3, restoration of parkin expression in parkin -
/- MEF (via the introduction of exogenous FLAG-tagged parkin) results in a 
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substantially slower growth rate. Thus, enhanced cellular proliferation in the 
absence of parkin appears to be quite a universal feature amongst dividing cells. 
 
Figure 4.9. Restoration of parkin expression in parkin null fibroblasts reduces their 
proliferation rate. (A) Graphical depiction of the rate of cell growth of primary 
embryonic fibroblasts derived from wild type (parkin +/+) or parkin null mice (parkin -/-). 
(B) As in (a) except that data for parkin +/+ MEFs is replaced by parkin null MEFs 
ectopically expressing FLAG-parkin. (Inset in both graphs shows anti-parkin 
immunoblot). 
 
4.2.9 Expression of cyclin D1 and phospho-Akt are upregulated in parkin 
null fibroblasts but is suppressed following parkin expression 
restoration. 
Supporting my observations above, parkin -/- MEFs also show elevated 
levels of cyclin D1 and phospho-AKT (S473) (Fig. 4.10A). These observations 
were essentially duplicated in MEFs derived from a separate line of parkin null 
mice [generated by means of a targeted deletion of parkin exon 3 (Fujiwara et al., 
2008)] (Fig. 4.10B), suggesting that my observations are not unique to a particular 
parkin KO line.  




Figure 4.10. Parkin null MEFs exhibit enhanced expression of cyclin D1 and 
phospho-Akt (A) Immunoblots showing the levels of cyclin D1 (top) and phospho-Akt 
(S473) (bottom) in parkin +/+ and -/- MEFs. These experiments were repeated at least 
three times and the relative densitometric units of cyclin D1/actin and phospho-Akt/Akt 
in parkin +/+ and parkin -/- MEFs are presented as histogram alongside their respective 
immunoblots. (B) Immunoblots showing the levels of cyclin D1 (top) and phospho-
Akt (S473) (bottom) in parkin +/+ and -/- immortalized MEFs derived from exon 
3-deleted parkin mice (see text). These experiments were duplicated. 
 
Importantly, restoration of parkin expression in parkin -/- MEF results in a 
significant reduction in the expression of cyclin D1 and phospho-AKT (S473) 
(Fig. 4.11).  
 
 
Figure 4.11. Parkin expression restoration in parkin -/- MEFs suppresses expression 
of cyclin D1 and phospho-Akt (A) Immunoblots showing the levels of cyclin D1 (top) 
and phospho-Akt (S473) (bottom) in parkin -/- MEFs ectopically expressing FLAG-
parkin. These experiments were repeated at least three times and the relative 
densitometric units of cyclin D1/actin and phospho-Akt/Akt in parkin -/- and parkin -/- (+ 
FLAG-parkin) MEFs are presented as histogram alongside their respective immunoblots.  
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Taken together, my results support an inverse association between parkin 
function and cellular proliferation, and identified cyclin D1 and phospho-Akt 
(S473) as key common denominators of the functional relationship between 




In the earlier chapter, I have shown that the expression of parkin in 
otherwise parkin-deficient glioma cells mitigate their rate of cellular proliferation. 
Here, I went on to determine if this parkin-induced suppression of glioma cell 
proliferation is due to its influence on the cell cycle program. My study presented 
in this chapter revealed that parkin is indeed capable of exerting a negative effect 
on the cell cycle program of U-87MG cells but curiously through the down-
regulation of cyclin D1 instead of cyclin E expression 
Previously, Staropoli and colleagues have shown that the deficiency of 
parkin potentiates the accumulation of cyclin E protein in cultured postmitotic 
neurons exposed to the glutamatergic excitotoxin kainate, suggesting that the cell 
cycle regulator, cyclin E, could be regulated by parkin in neurons (Staropoli et al., 
2003). Further to this, expression of wild type parkin (but not mutant parkin 
lacking exon 3-4) was shown to degrade cyclin E in HEK293T cells (Ikeuchi et 
al., 2009). These lines of evidence suggest the ability of parkin to negatively 
regulate the levels of cyclin E and thereby promoting the cells to halt at the G1-
phase. I therefore examined the levels of cyclin E in parkin-expressing glioma 
cells. Unexpectedly, my results suggest that cyclin E is not the critical player 
underlying parkin-mediated effects on glioma cells. However, it is noteworthy to 
highlight that we have previously observed no significant change in cyclin E 
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expression between parkin-deficient and parkin-expressing breast cancer cells 
(Tay et al., 2010). Moreover, cyclin E levels are also not appreciably altered in 
cells or tissues derived from parkin null mice relative to control (Fu et al., 2004).  
Instead of cyclin E, cyclin D1 appears to be the important parkin-linked 
cell cycle factor in glioma cells. Supporting this, the level of cyclin D1 in parkin-
expressing U-87MG cells is significantly reduced both at the level of mRNA 
transcript and protein. As cyclin D1 induction is considered a rate-limiting step in 
cell cycle progression through the G1 phase (Fu et al., 2004), its suppression by 
parkin is expected to impact on the rate of cellular proliferation, which is 
essentially what I have observed. Indeed, both parkin-expressing asynchronous 
and synchronous U-87MG cells exhibit a higher tendency to accumulate in the G1 
phase. In contrast, glioma cells that express a catalytic mutant of parkin that does 
not exert any observable effects on cyclin D1 level did not show such a 
characteristic. Together, these findings suggest that parkin acts on cyclin D1 to 
regulate the cell cycle program in glioma cells.   
 I next went on to determine if parkin would affect any important pathways 
that have been implicated in the gliomagenesis. The PI3K/Akt survival pathway is 
one of the major survival pathways in gliomagenesis is in caused by frequent 
PTEN mutations in gliomas especially glioblastoma multiforme (GBM) which 
lead to the hyperactivation of the PI3K/Akt signaling pathway that promotes cell 
survival. Maximum activation of Akt requires T308 phosphorylation by PDK1 
and S473 phosphorylation by PDK2, a kinase whose exact identity remains rather 
obscure although biochemical studies suggested mTOR complex 2 as a likely 
candidate (Hresko et al., 2005). Interestingly, the expression of wild type parkin 
reduced the levels of phosphorylated Akt specifically at serine 473 position but 
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not at threonine 308 position, suggesting that parkin acts on PDK2 instead of 
PDK1. Consistent with this, the levels of PDK1 in parkin-expressing glioma cells 
are comparable to their control counterparts. In addition, the catalytic activity of 
parkin was found to be required for this ability as catalytically inactive mutant 
parkin (T415N) does not reduce the level of phosphorylated Akt at serine 473 
position.  
One of the main factors that contribute to cancer cell growth is oncogenic 
signaling caused by mutated forms of receptor tyrosine kinase. EGFR gene 
amplification occurs in approximately 40% of all known GBM and this usually 
leads to enhanced EGF signaling and hyperactivation of its tyrosine kinase 
activity within the cell contributing to oncogenic signaling Even under EGF 
stimulation conditions, parkin-expressing U-87MG cells had reduced level of 
phosphorylated Akt (S473) as compared to the vector control. Notably, parkin 
exerts its effect on Akt S473 phosphorylation in quiescent cells as well as in those 
treated with EGF. This observation is in contrast to a previous report by Fallon 
and colleagues who demonstrated in COS-7 and HEK293 that parkin-mediated 
monoubiquitination of the adaptor protein Eps15 inhibits its ability to initiate 
receptor down-regulation and leads to enhanced EGF receptor signaling as well as 
downstream EGF-induced Akt signaling (Fallon et al., 2006). Similarly, we have 
also reported an apparent increase in Akt S473 phosphorylation in parkin-
expressing MCF-7 cells compared to control (Tay et al., 2010). I am therefore 
puzzled by this discrepancy but noted that my current observation in U-87MG 
cells is reproducible in MEFs prepared from wild type and parkin null mice, 
suggesting that parkin-mediated effects on Akt signaling may be dependent on the 
cell type examined. Notwithstanding this, over-activation of Akt signaling is a 
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frequent feature of tumors including gliomas. That parkin can down-regulate Akt 
signaling in U-87MG cells would offer a mechanism underlying its tumor 
suppressor function. In addition, parkin expression in U-87MG cells was shown to 
down-regulate levels of phospho-GSK3β and total GSK3β proteins (results not 
shown). 
Following these sets of exciting data, I wanted to have a more 
comprehensive view of how parkin would affect the global regulation of genes, I 
subjected parkin-expressing and vector control U-87MG cells through a series of 
microarray experiments and analysis. This is to determine if there were any subset 
of genes that might perhaps provide us with a clue as to what are the major set of 
genes regulated by parkin and if possible, to elucidate a set of genes which might 
perhaps be used as a key signature for potential early diagnosis of glioma cancer 
and prediction of survivability in patients. The outcomes of my analyses are 
presented in the next chapter. 




PARKIN PATHWAY ACTIVATION PREDICTS SURVIVAL OUTCOME 
OF GLIOMA PATIENTS 
 
5.1 Overview 
In the previous two chapters, I have presented results demonstrating that 
parkin is a negative regulator of glioma cell proliferation and that it exerts its 
tumor suppressing function directly through influencing components of the cell 
cycle machinery and indirectly through the down-regulation of the growth-
promoting Akt pathway. However, as cancer development is a multi-step process 
involving a wide spectrum of factors, it is conceivable that parkin’s effect on 
glioma growth is not limited to the above pathway and may involve other players. 
I was therefore naturally interested to know the global gene expression changes in 
glioma cells triggered by parkin. Because my in vivo data suggest that parkin 
expression may also help improve the survival outcome in animals with gliomas, I 
was at the same time curious to know if the same is true in human glioma patients 
and if there exists a “parkin signature pathway” that may help prognosticate 
cancer survival. Notably, current glioma prognostication usually relies on histo-
pathological analysis. Such morphology-based investigation has its limitations as 
gliomas are increasingly recognized to be molecularly heterogeneous even within 
the same histological subgroup. A “parkin signature pathway” that can be used as 
a complementary prognostication tool to histo-pathological analysis will be of 
obvious clinical value. 
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Here, I subjected parkin-expressing and vector-control U-87MG cells to 
microarray analyses using Affymetrix chips and noted significant difference in 
global gene expression between the two types of cells. Among these, one gene 
that caught our attention is VEGFR-2 (also known as KDR), whose expression is 
reduced by nearly 4-fold in U87-parkin compared to vector control. Separately, I 
found that parkin expression alone appears to correlate inversely with glioma 
mortality. As maximal and meaningful data mining from micro-array analyses 
requires expert help from a bioinformatician, I have sought help from Ms. Felicia 
Ng (a bio-informatician from the Singapore Institute for Clinical Sciences) to 
further analyze the micro-array data. Based on the changes in gene expression 
observed between control and parkin-expressing U-87MG cells, we were able to 
derive a parkin gene signature. Importantly, we show here that the parkin 
signature consistently stratified patient survival outcome in the 2 major 
independent datasets with diverse glioma variants, thereby strengthening the 
significance of the signature initially derived from limited cell line numbers. 
Taken together, my results strongly established a role for parkin in gliomagenesis, 













5.2.1 Parkin expression in U-87MG cells significantly affects global gene 
expression  as compared to the vector control 
To examine if exogenous parkin expression in otherwise parkin-deficient 
U-87MG glioma cells will lead to global gene expression changes, 3 parkin 
expressing U-87MG stables (PK7, PK19, PK25) and 3 respective vector controls 
(V8, V17, V22) (each in triplicates) were subjected to microarray array analysis 
using the Affymetrix GeneChip Human Gene 1.0 ST Array and subsequently 
analysed using the analysis software Biotique XRAY. The principal component 
analysis (PCA) plot revealed distinctive differential expression of subset of genes 
between the parkin expressing U-87MG cells and their respective vector control 
as segregated by the dotted line (Fig. 5.1). 
 
Figure 5.1 Principal component analysis (PCA) plot showing different 
transcriptional profile of genes between the parkin expressing U-87MG cells and 
their respective vector controls. Normalized transcriptional profiles of parkin 
expressing U-87MG (PK7, PK19, PK25) and vector controls (V8, V17, V22).  
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5.2.2 VEGFR-2 expression are significantly reduced in parkin-expressing 
glioma cells 
A more detailed analysis of the above micro-array data reveals that the 
most significant alterations are a near 16-fold upregulation of the gene encoding 
Interleukin 13 receptor and a 10-fold repression of the gene encoding a 
transmembrane protein (Fig. 5.2). Notably, the expression of cyclin D1 transcript 
is reduced by about 2-fold in the presence of parkin over-expression (not shown in 
Fig. 5.2), which is consistent with the results presented in the previous chapter.  
 
Figure 5.2 Parkin gene signature. Heatmap of the Parkin signature derived from the 
microarray dataset  
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However, one gene that immediately caught my attention is VEGFR-2 
(also known as KDR), whose expression is reduced by nearly 4-fold in U87-parkin 
compared to vector control (Fig. 5.3A). Aberrant VEGFR-2 expression is 
associated with a wide variety of cancers, including gliomas. Consistent with the 
microarray analyses result above, anti-VEGFR-2 immunoblotting revealed a 
significant reduction in parkin-expressing U87 cells, but not in those that 
expresses the T415N mutant, as compared to control cells (Fig. 5.3B).  Moreover, 
VEGFR-2 level is elevated in parkin null MEFs (Fig. 5.3C) which decreases upon 













Figure 5.3 VEGFR-2 expression is downregulated in parkin-expressing U-87MG 
cells. (A) Immunoblots showing the levels of VEGFR2 in lysates prepared from native U-
87MG cells (U87), U87-vector (Vector) and U87-FLAG-parkin (PK7, 19 & 25). The anti-
VEGFR2 immunoblot from three independent experiments were used to derive the 
relative densitometric units of VEGFR2 (normalized to respective actin loading control 
level), which is presented as a histogram (bottom). (B) As in (A) except U87-FLAG-
parkin (PK7, 19 & 25)-expressing cells were replaced by U87-FLAG-parkin T415N 
(TN5, 7 & 8)-expressing cells. (C-D) Immunoblots (left) and histogram (right) showing 
the levels of VEGFR2 in (C) parkin +/+ and -/- MEFs and parkin -/- and parkin -/- stably 
expressing FLAG-parkin (+PK) MEFs.  
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Thus, the expression of VEGFR-2, along with cyclin D1 and phospho-
AKT (S473), all of which are known to enhance cellular proliferation, are 
significantly elevated in glioma cells and MEFs deficient in functional parkin. 
 
5.2.3 Interleukin 13 receptor is significantly upregulated in parkin-
expressing-U-87MG cells 
As mentioned earlier, the top induced gene in parkin-expressing U-87MG 
cells is interleukin 13 receptor-α2 (IL-13Rα2). It is noteworthy that IL-13Rα2 is 
commonly found to be overexpressed in human malignant glioma cell lines and 
primary tumor cell cultures. Importantly, cytotoxin against IL-13Rα2 was actually 
found to be highly selective in killing human GBM-derived cells in vitro while 
leaving normal cells including endothelial cells, immune cells and neuronal cells 
generally unaffected (Husain et al., 2003). This might present a potential mode of 
therapeutics in which expression of parkin could sensitize gliomas to IL-13Rα2 
cytotoxin therapy against gliomas. I was therefore keen to examine if IL-13Rα2 
protein expression is correspondingly upregulated in parkin-expressing U-87MG 
cells. As expected, anti- IL-13Rα2 immunoblotting of cell lysates prepared from 
the various stable U-87MG cell lines revealed a significant upregulation of the 






Figure 5.4 IL-13Rα2 expression is upregulated in parkin-expressing U-87MG cells. 
(A) Immunoblots showing the levels of VEGFR2 in lysates prepared from native U-
87MG cells (U87), U87-vector (Vector) and U87-FLAG-parkin (PK7, 19 & 25). 
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5.2.4 Other notable gene expression changes in parkin-expressing-U-87MG 
cells 
Besides VEGFR2 and IL-13Rα2, two other potentially important genes 
that were differentially regulated in parkin-expressing U-87MG cells relative to 
control include FK506 binding protein 5 (FKBP5) and transgelin. Previously, 
FKBP5 was found to be upregulated in gliomas and inhibition of FKBP5 
expression was found to suppress cellular proliferation and overexpression of 
FKBP5 was found to enhance cell growth (Mikkelsen et al, 2008). In addition, 
FKBP5 was also found to be involved in the nuclear factor-kappa B (NF-ĸB) 
pathway activation in glioma cells through the regulation of expression of IKKα 
and phosphorylated NF-ĸB. The inhibition of FKBP5 was shown to sensitize both 
PTEN-positive and PTEN-negative cells rapamycin-resistance glioma cells to 
rapamycin treatment (Mikkelsen et al, 2008). 
In good agreement with the microarray data, anti-FKBP5 immunoblotting 
revealed an obvious and significant reduction in the levels of FKBP5 in parkin-
expressing glioma cells relative to vector control (Fig. 5.5 A-B). Again, parkin 
activity is needed here as U-87MG cells expressing the catalytic null parkin 
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Figure 5.5 Parkin expression downregulates the levels of FKBP5 in U-87MG cell line 
as compared to the vector control. (A) Anti-FKBP5 immunoblots of total lysates 
prepared from native U-87MG (U87), U-87MG vector control (vector) and parkin-
expressing stable clones (#7, 19 & 25). Equal loading of the different lysates was verified 
by anti-actin immunoblotting. (B) Bar-graph depicting densitometric readings of 
normalized FKBP5 levels in various U-87MG native, vector control and parkin-
expressing stable cell lines. These experiments were performed three times. (*P < 0.05, 
Student’s t-test) (C) Anti-FKBP5 immunoblots of total lysates prepared from native U-
87MG (U87), U-87MG vector control (vector) and mutant parkin-expressing stable 
clones (#TN5, TN7 & TN8). Equal loading of the different lysates was verified by anti-
actin immunoblotting. (D) Bar-graph depicting densitometric readings of normalized 
FKBP5 levels in various native U-87MG (U87), U-87MG vector control (vector) and 
mutant parkin-expressing stable clones (#TN5, TN7 & TN8). 
 
 
5.2.5 Parkin expression downregulates levels of microRNA-21 (miR-21) and 
microRNA-155 (miR-155) in glioma cells 
MicroRNAs (miRNAs) are a class of small, non-protein coding, 
endogenous RNAs that are important regulatory molecules in the regulation of 
gene expression by translation repression, mRNA cleavage and mRNA decay 
initiated by miRNA-guided rapid deadenylation. In addition to this, recent studies 
showed miRNAs to be involved in cell proliferation, cell signaling and apoptosis 
processes (Zhang et al, 2007). MicroRNA-21 (miR-21) was previously identified 
as an anti-apopototic factor in glioblastomas when it was demonstrated that 
knockdown of miR-21 in cultured glioblastoma cell lines triggered the caspase 
activation and associated apoptotic cell death (Chan et al, 2005). miR-21 was 
previously found to be overexpressed in grade II-IV astrocytomas (Conti et al, 
2009) and was shown to promote glioma invasion by targeting matrix 
metalloproteinase regulators (Gabriely et al, 2008). Besides astrocytomas and 
glioblastomas, the overexpression of miR-21 was also demonstrated in a wide 
range of malignancies including breast, colon, gastric, lung, pancreas and prostate 
cancer (Volinia et al, 2006). Similarly, miR-155 was previously shown to be 
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overexpressed in a breast cancer (Iorio et al, 2005), lung cancer (Yanaihara et al, 
2006), Hodgkin disease (Kluiver et al, 2005), primary mediastinal non-Hodgkin 
lymphoma (Kluiver et al, 2005) and a variety of lymphomas and leukemias which 
includes pediatric Burkitt lymphoma (Metzler et al, 2004), chronic lymphocytic 
leukemia (CLL) (Calin et al, 2005) and acute myeloid leukemia (AML) (Garzon 
et al, 2008). 
Interestingly, the levels of miR-21 and miR-155 both appear to be affected 
by parkin. Indeed, the expression of parkin in U-87MG cells results in a 
significant downregulation of the levels of miR-21 by 1.6 folds (p-value < 0.001) 
as compared to the U-87MG vector controls, as revealed by the microarray data 
analysis. I have validated this finding by means of real-time PCR which recorded 
on the average of about 7-fold reduction in miR-21 expression in parkin 
expressing U-87MG cells as compared to the U-87MG vector controls (Fig. 
5.6A). This value is in good agreement to that obtained through microarray. 
 
Figure 5.6 Parkin expression 
downregulates levels of microRNA-21 
(miR-21) and microRNA-155 (miR-155) 
in U-87MG cell line as compared to the 
vector control as verified by Real-Time 
polymerase chain reaction (PCR). (A) 
Bar-graph depicting the normalised real-
time quantification of miR-21 levels in U-
87MG vector control (vector) and parkin-
expressing stable clones (#7, 19 & 25). 
(B) Bar-graph depicting the normalised 
real-time quantification of miR-155 levels 
in U-87MG vector control (vector) and 
parkin-expressing stable clones (#7, 19 & 
25). These experiments were performed 
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In a similar fashion, parkin expression in U-87MG cells also significantly 
reduced the levels of miR-155, in this case by 2.3 folds (p-value < 0.05) and 2.5 
folds as revealed respectively by microarray analysis (not shown) and real time 
PCR (Fig. 5.6B). How parkin expression influences miR-21 and -155 expression 
is unclear at the moment. Future studies should help elucidate the mechanism 
involved. 
 
5.2.6 Parkin expression correlates inversely with glioma mortality 
I next sought to determine if parkin expression could portend prognosis in 
human glioma patients. For this purpose, I analyzed patient data from Rembrandt 
database (Madhaven et al., 2009) and found that that the mean expression of 
parkin is reduced in various glioma variants including astrocytomas, GBM and 
oligodendrogliomas (Fig. 5.7).  
Figure 5.7 PARK2 expression 
is consistently low in all tumor 
grades when compared to ‘non-
tumor’. (A-B) Boxplots show 
the range of PARK2 log 
expression values for expressing 
probesets (A) 207058_s_at and 
(B) 1555668_a_at in the 
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Importantly, Kaplan-Meier analysis revealed that glioma patients with poor parkin 
expression exhibit significantly higher mortality (Fig. 5.8), which is in agreement 
















Figure 5.8 Low PARK2 expression portends poor prognosis. Kaplan-Meier plot 
showing that patients with high PARK2 expression have better survival prognosis 
compared to patients with low PARK2 expression. 
 
My results thus suggest that parkin expression correlates inversely with cancer 
mortality and that pathways associated with parkin may affect survival outcome. 
The next step is to establish whether a parkin signature pathway could be derived 
from the microarray analysis data that might better interrogate the mortality of 
glioma patients. 
 
5.2.7 Refining Microarray Data 
The initial analysis of my microarray data was done using the Biotique 
XRAY software. As I was a novice at microarray analysis, I later sought the 
technical expertise from Ms. Felicia Ng (a bio-informatician from the Singapore 
Institute for Clinical Sciences) to further analyze the micro-array data. Our 
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microarray analysis results obtained were relatively consistent in terms of gene 
expression changes observed between control and parkin-expressing U-87MG 
cells. Notably, VEGFR-2 (KDR) gene was also featured as a top downregulated 

































Figure 5.9 Microarray analysis of gene expression changes in parkin expressing U-
87MG cells are compared to their vector controls. (Top panel) Heatmap analysis of the 
differential gene expression between parkin expressing U-87MG and their respective 
vector control. (Bottom panel) Top 10 repressed or induced genes upon parkin over-
expression. The log fold change difference is as shown. Gene symbol description can be 
found in table 5.1 below. 
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5.2.8 Parkin gene signature predicts survival outcome of human glioma 
patients 
We next sought to (i) determine if differentially regulated genes between 
parkin-expressing and non-expressing U-87MG cells could stratify patient 
survival in public clinical glioma databases, and (ii) evaluate if this “parkin 
signature” could serve as a metric to stratify gliomas of distinct clinical grades 
effectively by examining its enrichment pattern in the datasets.  
Recently, The Cancer Genome Atlas (TCGA) effort demonstrated that 
GBM can be molecularly sub-typed into groups distinguished by genetic 
aberrations and gene expression (Verhaal et al., 2010). These subtypes correlate 
with unique clinical profiles, illustrating that gene expression drives GBM disease 
progression and survival outcome. This provides a basis for our approach in 
evaluating gene expression perturbations arising from parkin-expressing and non-
expressing U-87MG cells. We carried out the following: Using a larger collection 
of 802 probesets (top 20 ranking genes shown in Fig. 5.9), we determined by 
Gene Set Enrichment Analysis, the biological pathways enriched between parkin-
expressing and non-expressing U-87MG cells. In particular, this 802-gene 
signature enriched for pathways in “programmed cell death” and “apoptosis” (Fig. 
5.10). Next, we pared down this gene list with more stringent criteria and defined 
survival correlations using an adaptation of the “Connectivity Map” method 
(Lamb et al., 2006). While the Connectivity Map method was originally 
conceptualized to connect biological states of interest (represented by a gene 
signature) to the action of small molecule therapeutics (a database of reference 
profiles), our study attempts to make a connection between the biological state of 
parkin-expression to patient tumor expression profiles.  A recent study (Ooi et al., 
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2009) has shown that this method can be used effectively to score tumor 
expression profiles that correspond to the degree of oncogenic pathway activation.   
 
Figure 5.10. Parkin gene set enrichment and network analysis. Significantly enriched 
gene sets discovered using GSEA on the 802 differentially expressed probesets between 
Parkin-expressing and Vector samples. 
 
Likewise, we have adapted the Connectivity Map methodology to score 
GBM expression profile databases based on the extent of pathway activation 
associated with the parkin signature. This strategy comprises 4 steps: (i) First, we 
defined a “parkin signature” – a set of genes exhibiting altered expression after 
specific perturbation of the parkin gene in our well-defined in vitro system, (ii) 
Second, we generated 2 databases of reference gene expression profiles from two 
major public clinical glioma databases – Rembrandt and Freije (Madhaven et al., 
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2009, Freije et al., 2004), (iii) Third, using a non-parametric, rank-based pattern 
matching procedure, we mapped the parkin signature onto each patient gene 
expression profile and calculate activation scores based on the strength of 
association to the parkin signature, and finally (iv) the patients were sorted 
according to their pathway activation scores. Accordingly, we determined genes 
differentially regulated between parkin-expressing and non-expressing U-87MG 
cells, with FDR~0 and log2FC≥1.2, generating a “parkin signature” This signature 
consistently stratified patient survival in the 2 clinical databases (see table below 
and Fig. 5.11).  
Of note, the parkin signature successfully assigned significant activation 
scores to 20-30% of patients, with the rest of patients showing no association. 
Further, in both databases, we observed that patients with a positive activation 
score (i.e. ROS+; strong concordance with parkin signature) tended to align with 
lower tumor grades and/or the oligodendroglioma histology, frequently associated 
with better prognosis (Caimcross et al., 1998). In contrast, patients with a negative 
activation score tended towards grade IV. Finally, we determined the prognostic 
power of the parkin signature using a Cox regression model. Our data indicate that 
the parkin signature is an independent predictor of glioma disease progression and 
survival, in addition to age and histology which are the current clinical indicators 
(Louis et al., 2007). Further, we observed that in both databases, the parkin 
signature predicted survival outcome better than histology alone. Taken together, 
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we provide strong evidence that parkin expression correlates inversely with 
glioma mortality and its pathway activation is predictive of survival outcome. 
Figure 5.11 Parkin gene signature is predictive of survival outcome of human 
glioma patients. The 50-gene signature stratifies patient survival in 3 public glioma 
databases: (A) Rembrandt and (B) Freije. Activation scores denote ranking of gene 
signature likeness to clinical database gene expression, and patient survival is linked to 
this ranking. A positive score represents patients with similarity to parkin-overexpression, 
while a negative score denotes patients with inverse relation, i.e. similarity to vector-only 
cells. The tumor grade is scored for individual patients below the activation score chart. 
Survival data are plotted as Kaplan-Meier curves. (+), concordance of parkin-
overexpression gene signature with patients’ gene expression and consequently better 
survival; (-), inverse relation of parkin-overexpression (i.e. similarity to vector-only 
expression) with clinical database gene expression and consequently poorer survival. 
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5.3 Discussion 
In the previous chapter, parkin was shown to mitigate cell cycle 
progression of a representative glioma cell line, U-87MG, through the reduction 
of cyclin D1 and phosphorylated Akt (S473). Following these results, I wondered 
what would be the global subset of genes that could be regulated by expression of 
parkin in U-87MG cells. From the microarray analysis, the expression of parkin 
was found to differentially regulate 802 genes and from which cyclin D1 was also 
found to be transcriptionally downregulated by about 2 fold which correlated with 
the reduction in cyclin D1 levels as mentioned in the chapter 4. In addition, the 
angiogenic VEGFR2 was found to be downregulated by about 4.7-folds in parkin 
expressing U-87MG cells as compared U-87MG native and vector control cells. 
Although predominantly found on endothelial cells, VEGFR have also been 
detected on cancer cells including gliomas, suggesting a possible autocrine effect 
on their growth (Masood et al., 2001) Importantly, autocrine regulation of GBM 
cell cycle progression and viability through VEGF-VEGFR2 interplay involves 
co-activation of the PI3/Akt pathway (Knizetova et al., 2008) which parkin 
appears to regulate. Upon further examination, the protein level of VEGFR2 was 
also found to be consistently downregulated by about 3-folds in parkin expressing 
U-87MG cells as compared U-87MG native and vector control cells. Importantly, 
the expression of mutant form of parkin, T415N does not seem to reduce the 
levels of VEGFR2. This demonstrates that the reduction in the levels of VEGFR2 
is dependent upon parkin’s catalytic activity.  
A number of other differentially expressed proteins and microRNAs like 
FKBP5, miR-21 and miR-155 were also identified from the microarray analysis. 
The transcript and protein levels of FKBP5 were found to be reduced as shown by 
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the microarray data analysis and immunoblotting. FKBP5 was previously found to 
be upregulated in gliomas and inhibition of FKBP5 expression was found to 
suppress cellular proliferation and overexpression of FKBP5 was found to 
enhance cell growth (Mikkelsen et al, 2008). Therefore, the reduction of FKBP5 
through the expression of parkin would have profound effects on the rate of 
cellular proliferation, NF-ĸB signaling pathway and the sensitization of glioma 
cells towards activators of autophagy treatments. Further to this, a novel effect of 
parkin was discovered when it was shown to be able to downregulate the levels of 
miR-21 by about 1.6 folds and miR-155 by about 2.3 folds accordingly. The 
downregulation of miR-21 through the expression of parkin could potentially have 
triggered the caspase activation and associated apoptotic cell death in the gliomas 
cells (Chan et al, 2005) and reduced glioma invasion by targeting matrix 
metalloproteinase regulators (Gabriely et al, 2008). The downregulation of miR-
155 could increase tumor protein 53-induced nuclear protein 1 (TP53INP1), a 
nuclear protein able to induce cell cycle arrest and apoptosis through caspase-3 
activation (Gironella et al, 2007). Taken as a whole, the multi-mechanistic parkin 
is potentially able to downregulate VEGFR2, exerts it anti-proliferative effects 
through the mitigation of cyclin D1 and phosphorylated Akt at serine 473 protein 
levels. Concurrently, the presence of parkin could also reduce the levels of 
oncogenic microRNAs like miR-21 and miR-155 and the absence of parkin could 
facilitate evasion from apoptosis or prevent dephosphorylation of Akt. 
 In order to determine whether parkin expression correlates with glioma 
patient prognosis and survivability in a clinical setting, patient data from a public 
clinical glioma database, Rembrandt (Madhaven et al., 2009) were analyzed and 
we found that that the mean expression of parkin is reduced in various glioma 
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variants including astrocytomas, GBM and oligodendrogliomas. But more 
importantly, the low parkin expression correlates with poor prognosis, which is in 
agreement with results derived from our mouse model. From the analysis of the 
microarray data, we generated a “parkin signature” which we showed to be able to 
accurately predict survival outcome better than histology. And taken as a whole, 
we provide strong evidence that parkin expression correlates inversely with 
glioma mortality and its pathway activation is predictive of survival outcome. 
 
 




GENERAL DISCUSSION AND CONCLUSIONS 
 
 The objective of this project is to clarify and understand the role of parkin 
in gliomagenesis. Upon completion of this project, I have managed to obtain 
several evidences that strongly support a negative role for parkin in 
gliomagenesis. Importantly, I have also identified a signature pathway of parkin 
that is of potential prognostic value. The functional role of parkin in 
gliomagenesis was elucidated using both parkin expression and knockout studies 
in both in vitro and in vivo systems. From these model systems, I was able to 
demonstrate that parkin expression regulates the cell cycle program and growth-
promoting signaling mechanisms of proliferating cells. When used to interrogate 
available human glioma database, I found that parkin activation pathway is also a 
predictor of the survival outcome of glioma patients. Taken together, the results 
presented in my thesis suggest that parkin is a key player in gliomagenesis, which 
is in addition to its established role in neurodegeneration. In this final chapter of 
my thesis, I will recap and evaluate the significance of my findings in perspective.  
 
6.1 A role for parkin in gliomagenesis – From brain degeneration to brain 
cancer 
Although a role for parkin in cancers may still come as a surprise to many, 
the 1.4Mb parkin gene is located within the common fragile site (CFS), FRA6E, a 
mutational hotspot on chromosome 6 that is frequently deleted in several tumor 
types including breast, ovarian, kidney and liver cancers (Cesari et al., 2003, 
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Denison et al., 2003, Picchio et al., 2004, Wand et al., 2004) FRA6E, along with 
other CFSs such as FRA3B, FRA16D and FRAXB, have been proposed to play a 
causal role in tumorigenesis and/or cancer progression (Druck et al., 1998) 
Notably, the FRA3B-associated FHIT and the FRA16D-associated WWOX genes 
are commonly deleted or altered in various tumor types. Further, several lines of 
evidence suggest that functionally, FHIT and WWOX act as tumor suppressors 
(Bednarek et al., 2001). The residence on FRA6E that the enormous parkin gene 
takes thus immediately suggests its potential association with cancers. Consistent 
with this, Cesari et al as well as a number of other groups have documented parkin 
gene alterations and concomitant reduction in parkin transcript abundance in a 
wide variety of cancers that includes breast, liver, non-small-cell lung and ovarian 
carcinoma (Tay et al., 2010, Fujiwara et al, 2008, Picchio et al., 2004, Denison et 
al., 2003). In addition, it was also shown that parkin was deleted in 2 out of 10 
GBM patients’ tumor samples and 4 out of 10 glioblastoma cell lines using high 
resolution microarray comparative genomic hybridization and molecular 
cytogenetic characterization techniques (Mulholland et al., 2006). Significant 
recurrent focal alterations involving homozygous deletions of parkin were also 
identified from 206 glioblastomas using three microarray platforms analyzed with 
multiple analytical algorithms (McLendon et al., 2008). More recently, Veeriah 
and colleagues have identified for the first time several inactivating somatic 
parkin mutations in GBMs and other malignancies and showed that cancer-
causing parkin mutations impair its ability to promote cyclin E degradation 
(Veeriah et al., 2009). Collectively, these studies strongly implicate a role for 
parkin as a tumor suppressor that is relevant to gliomagenesis. Here, I have 
extended these findings by showing that parkin expression is deficient in several 
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glioma cell lines and that the restoration of parkin expression in these cells indeed 
retards their growth. 
 
6.2 Parkin mitigates cell cycle progression at the G1-S phase transition 
through the downregulation of cyclin D1 level 
My study showed that parkin negatively influences the cell cycle program 
of U-87MG cells but interestingly through the down-regulation of cyclin D1 
instead of cyclin E expression. Staropoli and colleagues have previously shown 
that the deficiency of parkin potentiates the accumulation of cyclin E protein in 
cultured postmitotic neurons exposed to the glutamatergic excitotoxin kainate, 
suggesting that the cell cycle regulator, cyclin E, could be regulated by parkin in 
neurons (Staropoli et al., 2003). Veeriah and colleagues have also shown that 
somatic non-functional parkin mutations in cancer decrease parkin's E3 ligase 
activity, compromising its ability to ubiquitinate cyclin E and resulting in mitotic 
instability. Our results therefore differ from that reported by Veeriah and 
colleagues although we noted that they have used a different glioma cell line (i.e. 
T-98G) for their study. It is of importance to highlight that we have previously 
observed no significant change in cyclin E expression between parkin-deficient 
and parkin-expressing breast cancer cells (Tay et al., 20109). Moreover, cyclin E 
levels are also not significantly altered in cells or tissues derived from parkin null 
mice relative to control (Ko et al., 2005). On the other hand, the level of cyclin D1 
in parkin-expressing U-87MG cells is significantly reduced both at the level of 
mRNA transcript and protein. As cyclin D1 induction is required for cell cycle 
progression through the G1 phase (Fu et al., 2004), its suppression by parkin is 
expected to impact on the rate of cellular proliferation, which is essentially what 
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we have observed. Indeed, both parkin-expressing asynchronous and synchronous 
U-87MG cells exhibit a cell cycle arrest at the G1 phase. In contrast, the 
expression of a catalytic inactive mutant of parkin (T415N) in glioma cells does 
not exert any observable effects on cyclin D1 level. Together, these findings 
suggest that functional parkin acts on cyclin D1 to regulate the cell cycle 
progression in glioma cells.  Precisely how functional parkin regulates the 
expression of cyclin D1 is unclear to us at this present moment, although its 
apparent ability to down-regulate Akt phosphorylation may play a part here. 
Notably, the Akt pathway is known to enhance G1/S cell cycle progression 
through the inactivation of GSK3β, which results in increased cyclin D1 level 
(Liang et al, 2003). 
 
6.3 Expression of catalytically active parkin selectively reduces levels of 
Akt phosphorylation at Ser 473 in U-87MG cells 
Frequent PTEN mutations in gliomas which lead to the hyperactivation of 
the PI3K/Akt signaling pathway made the PI3K/Akt survival pathway one of the 
most important cell survival pathways in gliomas (Fan et al., 2010). Maximum 
activation of Akt requires both T308 phosphorylation by PDK1 and S473 
phosphorylation by PDK2, a multi subunit kinase whose exact identity remains 
rather obscure although biochemical studies suggested mTOR complex 2 as a 
likely candidate (Hresko et al., 2005). Interestingly, parkin expression leads to a 
specific reduction in Akt S473 (but not T308) phosphorylation, suggesting that 
parkin acts on PDK2 instead of PDK1. Consistent with this, the levels of PDK1 in 
parkin-expressing glioma cells are comparable to their control counterparts. 
Again, the effect of parkin on Akt S473 phosphorylation requires its catalytic 
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activity, as this activation step of Akt is not compromised in T415N mutant 
parkin-expressing U-87MG cells. Notably, parkin exerts its effect on Akt S473 
phosphorylation in quiescent cells as well as in those treated with EGF. This 
observation is in contrast to a previous report by Fallon and colleagues who 
demonstrated in COS-7 and HEK293 that parkin-mediated monoubiquitination of 
the adaptor protein Eps15 inhibits its ability to initiate receptor down-regulation 
and leads to enhanced EGF receptor signaling as well as downstream EGF-
induced Akt signaling (Fallon et al., 2006). Similarly, we have also reported an 
apparent increase in Akt S473 phosphorylation in parkin-expressing MCF-7 cells 
compared to control (Tay et al., 2010). I therefore remain intrigued by this 
discrepancy but noted that my current observation in U-87MG cells is 
reproducible in MEFs prepared from wild type and parkin null mice, suggesting 
that parkin-mediated effects on Akt signaling may be dependent on the cell type 
examined. Notwithstanding this, over-activation of Akt signaling is a frequent 
feature of tumors including gliomas. That parkin can down-regulate Akt signaling 
in U-87MG cells would offer a mechanism underlying its tumor suppressor 
function. 
  
6.4 Parkin expression reduces the levels of VEGFR2 and FKBP5 in U-
87MG cells 
The presence of parkin also clearly influences the expression of VEGFR2, 
one of the two high-affinity tyrosine kinase receptors involved in tumor 
neoangiogenesis. Although predominantly found on endothelial cells, VEGFR 
have also been detected on cancer cells including gliomas, suggesting a possible 
autocrine effect on their growth (Masood et al., 2001, Knizetova et al., 2008). 
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Importantly, autocrine regulation of GBM cell cycle progression and viability 
through VEGF-VEGFR2 interplay involves co-activation of the PI3k/Akt pathway 
(Knizetova et al., 2008), which parkin appears to regulate. It is interesting to note 
that the expression of VEGFR2 is dramatically reduced at both the mRNA and 
protein levels in parkin-expressing U-87MG relative to native or vector control 
cells. 
FKBP5 was found previously to be upregulated in variety of gliomas and 
inhibition of FKBP5 expression was found to suppress cellular proliferation and 
overexpression of FKBP5 was found to increase cell growth (Mikkelsen et al, 
2008). The transcript and protein levels of FKBP5 were reduced as indicated by 
the results from the microarray data analysis and immunoblotting. In addition, 
FKBP5 was found to be involved in the nuclear factor-kappa B (NF-ĸB) pathway 
activation in glioma cells through the regulation of expression of IKKα and 
phosphorylated NF-ĸB. The inhibition of FKBP5 was shown to sensitize both 
PTEN-positive and PTEN-negative cells rapamycin-resistance glioma cells to 
rapamycin treatment (Mikkelsen et al, 2008). Therefore, the reduction of FKBP5 
would conceivably have negative effects on the rate of cellular proliferation and 
NF-ĸB signaling pathway. 
Together, these results suggest that parkin-mediated suppression is not 
limited to a single pathway but potentially involves multiple intersecting pathways 
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6.5 Parkin expression reduces the levels of oncogenic miR-21 and miR-
155 in U-87MG cells 
A novel discovery was made when parkin was found to be able to 
downregulate the levels of miR-21 and miR-155. The downregulation of miR-21 
could possibly have triggered the caspase activation and associated apoptotic cell 
death in the gliomas cells (Chan et al, 2005) and reduced glioma invasion by 
targeting matrix metalloproteinase regulators (Gabriely et al, 2008). The 
downregulation of miR-155 could increase tumor protein 53-induced nuclear 
protein 1 (TP53INP1) to induce cell cycle arrest and apoptosis through caspase-3 
activation (Gironella et al, 2007). Due to time limitation, I was not able to pursue 
the relationship between parkin and these micro-RNAs in depth but this topic is 
clearly of interest and will undoubtedly be a subject of our lab’s future studies.  
 
6.6 Parkin gene signature predicts survival outcome of human glioma 
patients 
Although the findings above are interesting, I was cognizant that they were 
largely derived from a single glioma cell line, i.e. U-87MG. Whether the data is 
relevant to human gliomas was a concern. For this reason, I sought to determine if 
the data based on a limited cell line panel translated to significant clinical impact. 
The Cancer Genome Atlas (TCGA) efforts have recently highlighted the 
importance of gene expression in molecularly distinguishing GBM subtypes 
(Verhaak et al., 2010). These subtypes correlate with distinct genomic and clinical 
profiles, indicating that gene expression drives disease progression and survival 
outcome in GBM tumors. Similarly, Freije et al. defined survival stratification 
based on gene expression in glioma variants (Freije et al., 2004), thus 
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underscoring the significance of such molecular approaches. With the expert help 
from a bioinformatician, we thus analyzed 802 probe-sets differentially regulated 
between parkin-expressing and non-expressing U-87MG cells and identified 
several functional pathways by Gene Set Enrichment Analysis. We observed the 
following: (i) Parkin expression signature enriched for genes in “programmed cell 
death” and “apoptosis” functions; and (ii) In particular, we noted by network 
analysis that parkin expression repressed VEGFR-2 levels, leading to 
downregulation of the PI3K-AKT signaling axis, in agreement with my in vitro 
data. Recent work by TCGA highlighted the three major regulatory mechanisms 
in GBM growth: Receptor tyrosine kinase pathway/RAS/PI3K (AKT signaling), 
Rb signaling (G1/S progression) and p53 signaling pathways (senescence, 
apoptosis) (Atlas et al., 2008). These pathways are mutated in the majority of 
GBM patients (~80-90%). Further, significantly recurrent focal alterations not 
previously reported in GBMs, such as homozygous deletions in PARK2, 
emphasize that parkin may play a more central role in gliomagenesis that affects 
multiple downstream players. 
To determine the clinical impact of this parkin signature, we utilized the 
“Connectivity Map” method (Lamb et al., 2006). Previous studies have proposed 
using gene expression signatures to predict the activity of oncogenic pathways in 
cancer (Ooi et al., 2009). Here, we hypothesized that the strength of concordance 
of the parkin signature to the individual patient’s gene expression profile predicts 
the level of pathway activation which can subsequently be mapped to survival 
outcome. We pared down the gene list to 50 top-ranking candidates with more 
stringent criteria of log2FC>1.2 and FDR~0. This gene signature was then mapped 
onto publicly available clinical glioma databases – Rembrandt and Freije 
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(Madhaven et al., 2009, Freije et al., 2004). We successfully assigned parkin 
activation scores (with significant p-values between parkin+ and parkin- to reflect 
non-randomness of categories) to 20-30% of patients, while the remaining showed 
no difference. It is likely that this cohort of “parkin-zero” patients is a reflection of 
our filtering process. That is, we chose to examine two extreme scenarios of 
parkin+ and parkin- among only tumor patients/samples, and thus the most severe 
phenotypes; whereas no inclusion of normal brain tissue was used in the process. 
It is conceivable that with normal brain tissue as the comparator albeit their small 
numbers, more parkin-zero patients would have been assigned activation scores of 
significance. These remains to be investigated although we believe a more robust 
method to compare tumor and normal brain tissue would be to analyze their 
genomic aberrations (copy number, SNP). We show here that the parkin signature 
consistently stratified patient survival outcome in the 2 major independent datasets 
with diverse glioma variants, thereby strengthening the significance of the 
signature initially derived from limited cell line numbers. We noted that the 
signature was marginally insignificant in TCGA, possibly due to the fact that 
TCGA comprises only GBM specimens and thus less molecular heterogeneity. 
This trend was also observed by Yan et al. (Yan et al., 2011) in which their gene 
signature of interest displayed marginal significances in “all GBM” databases, 
TCGA (Atlas et al., 2008) and Murat (Murat et al., 2008). By inference, our data 
would seem to support a role for parkin as a metric to stratify gliomas of distinct 
clinical grades. We thus examined the patient tumor grades corresponding to their 
ranked parkin signature enrichment profiles in the 2 clinical databases. 
Interestingly, the parkin+ activation scores enriched for patients with lower, less 
aggressive tumor grades, or the oligodendroglioma histology which is typically 
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associated with better prognosis (Caimcross et al., 1998). In contrast, parkin- 
patients were mainly grade IV GBM. Our Cox regression model in the two 
clinical databases suggests that the parkin signature predicts for survival better 
than the current clinical indicator, histology. Our data therefore indicates that the 
parkin signature defines a role for molecular heterogeneity in contributing to 
survival outcome that cannot be fully accounted for by histology alone. This 
underscores the limitation of morphology-based pathological diagnoses which 
currently determine the type of glioma therapeutic regimens undertaken in the 
clinic. Thus, a re-examination of this 50-gene list including PARK2, could 
conceivably provide useful prognostic indicators to monitor disease progression.  
 
6.7 Conclusions 
The overall objective of my project is to understand and establish a role for 
parkin in gliomagenesis. This knowledge will enable us to better understand the 
role of parkin in cancer as a whole and whether its proposed anti-cancer function 
is relevant to glioma growth. At the moment, there are numerous reports relating 
parkin to cancer but few have provided a mechanism as to how parkin could 
suppress tumor formation. As stated in Chapter 1, my specific objectives were as 
follows: 
 
I. To characterize the expression of parkin in glioma cells and examine the 
effects of parkin over-expression on the rate of glioma cell proliferation 
both in vitro and in vivo. 
II. To dissect the mechanism underlying parkin-mediated tumor suppression 
(of glioma growth). 
General Discussion and Conclusions     137 
 
III. To validate the results obtained (from above aims) in human biopsy 
samples and/or glioma databases. 
 
In relation to these objectives, I could now make the following conclusions: 
 
I. Parkin deficiency is a characteristic of glioma cells and restoration of its 
expression mitigates glioma growth both in vitro and in vivo.  
 
II. Parkin-mediated suppression of glioma growth is related to its ability to 
downregulate the VEGFR2-Akt-cyclin D1 pathway, although the entire 
spectrum of the parkin tumor suppression pathway is not restricted to 
these components and may involve other components such as FKBP and 
miR-21 and -155. 
 
III. Importantly, parkin gene signature predicts survival outcome of human 
glioma patients, which validate the above findings derived from glioma 
cell lines. 
 
Taken together, my Ph.D. work strongly established a role for parkin in 
gliomagenesis, and further suggests that disease progression may be a manifest of 
parkin pathway inactivation. A model summarizing my findings is provided 
below. 
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Figure 6.1 Proposed model of parkin’s anti-proliferative effects in gliomas. Parkin 
downregulates the levels of VEGFR2 which leads to a reduction in the levels of phospho-




6.8 Future Work 
 
 Parkin may participate in gliomagenesis through the VEGFR2-Akt-cyclin 
D1 pathway, however the precise mechanism for which parkin acts on this 
pathway is unknown. Future studies can be focused on whether parkin could 
interact and ubiquitinate these substrates directly and as a result reduce the levels 
of these proteins in the cell. Genetic studies focusing on the interaction of parkin 
with other oncogenes and tumor suppressor genes could also be investigated in 
various animal models like drosophila or mouse models to determine if parkin 
could indeed play a synergistic role with these cancer-causative genes. 
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